Drug,Gene,ICD,gene_ICD_ref,gene_ICD_TRUE_FALSE,gene_ICD_sentence,drug_gene_ref,drug_gene_TRUE_FALSE,drug_gene_sentence,Observations,keep_new
DAIDZIN,ALDH2,AGE RELATED OSTEOPOROSIS,"Pmcoa_4085729,Medline_28474171,Pmcoa_5544803,Medline_22508505",TRUE,These results provide new insight into regulation of osteoporosis in a subset of individuals with ALDH2*2 and in alcoholic patients and suggest a novel strategy to promote bone formation in such osteopenic diseases.,"Patent_EP0592583B1,Patent_EP0592583A1,Pmcoa_4838626,Medline_8032168,Pmcoa_5226516,Medline_19673742,Medline_8433985,Medline_24273684,Patent_US6255497,Medline_28219011,Medline_21123025,Pmcoa_5094945,Pmcoa_5667593,Pmcoa_5104933,Medline_30538807,Pmcoa_6309505,Medline_15377279,Medline_30187866,Medline_25084483,Medline_25543082,Pmcoa_3684953,Pmcoa_6261243,Patent_US8124389,Medline_26221217,Medline_29047162,Pmcoa_5654254,Patent_US20090124672A1,Pmcoa_5271370,Patent_US20090124672,Patent_EP2751090A1,Medline_9482862,Medline_9050837",TRUE,ALDH2 can be directly activated by the activator Alda-1 and inhibited by the inhibitor Daidzin.,,new
ACTINONIN,ANPEP,AGE RELATED OSTEOPOROSIS,"Pmcoa_3699501,Pmcoa_4128281",FALSE,Adipokine adiponectin (APN) has been recently reported to play a role in regulating bone mineral density (BMD),"Patent_US5021549,Patent_EP1675594A2,Patent_WO2005037779A2,Medline_10873564,Patent_US20050113310,Pmcoa_5622148,Medline_16778789,Patent_US20040147434,Patent_US20070042938,Medline_17981718,Pmcoa_5385526,Medline_14757368,Medline_12443882,Medline_18973761,Medline_19264392,Medline_7961121,Patent_US8263636,Pmcoa_4658336,Patent_US20070037752,Patent_US20110117069,Patent_US20070078130,Patent_US20140336159,Patent_WO1998044923A1,Pmcoa_2821472,Patent_WO2013052844A1,Patent_US20070037785,Medline_9602161,Pmcoa_3359464,Patent_EP0167936A2,Patent_US4663342",-,,,keep
DHEAS,AR,AGE RELATED OSTEOPOROSIS,"Medline_27402268,Medline_15987833,Patent_EP1480634B1,Patent_US8088828,Patent_US7776921,Medline_15511132,Medline_17907058,Medline_20348548,Patent_WO2001073116A2",TRUE,"BA321, a novel carborane analog that binds to androgen and estrogen receptors, acts as a new selective androgen receptor modulator of bone in male mice.","Medline_17548088,Medline_15249140",TRUE,"Treatment of granulosa cells with 20 ng/mL DHEAS increased the expression of androgen receptor, aromatase, 3-beta-hydroxysteroid dehydrogenase, and cyclooxygenase-2, reduced the expression of estrogen receptor beta, and increased estrone and estradiol levels, but had no effect on progesterone, androstenedione, or testosterone levels.",,keep
CYPROTERONE,AR,AGE RELATED OSTEOPOROSIS,"Medline_27402268,Medline_15987833,Patent_EP1480634B1,Patent_US8088828,Patent_US7776921,Medline_15511132,Medline_17907058,Medline_20348548,Patent_WO2001073116A2",TRUE,,"Medline_15242831,Medline_19383315,Medline_12020745,Medline_14643695,Pmcoa_4829986",TRUE,"Furthermore, this effect was blocked by the androgen receptor antagonist cyproterone. ",,keep
OXANDROLONE,AR,AGE RELATED OSTEOPOROSIS,"Medline_27402268,Medline_15987833,Patent_EP1480634B1,Patent_US8088828,Patent_US7776921,Medline_15511132,Medline_17907058,Medline_20348548,Patent_WO2001073116A2",TRUE,,"Pmcoa_1828036,Medline_15219414",TRUE,Increased nuclear fluorescence of the androgen receptor and increased cellular type I collagen were observed with oxandrolone at 15 and 30 μg/mL but not at lower doses.,,keep
ENOBOSARM,AR,AGE RELATED OSTEOPOROSIS,"Medline_27402268,Medline_15987833,Patent_EP1480634B1,Patent_US8088828,Patent_US7776921,Medline_15511132,Medline_17907058,Medline_20348548,Patent_WO2001073116A2",TRUE,,"Patent_US20170319597,Patent_WO2017066827A1,Medline_26393303",TRUE,"The selective androgen receptor modulator, GTx-024 (enobosarm), is being investigated for cancer cachexia, sarcopenia, and muscle wasting diseases.",,keep
PHENYL CYANIDE,AR,AGE RELATED OSTEOPOROSIS,"Medline_27402268,Medline_15987833,Patent_EP1480634B1,Patent_US8088828,Patent_US7776921,Medline_15511132,Medline_17907058,Medline_20348548,Patent_WO2001073116A2",TRUE,,"Patent_US9205102,Medline_10966753",FALSE,"4-[4, 4-Dimethyl-3-(4-hydroxybutyl)-5-oxo-2-thioxo-1-imidazolidinyl]-2-+ ++trif luoromethylbenzonitrile (RU 59063) is a prototype of a new class of high-affinity nonsteroidal androgen receptor (AR) ligands.",,new
AMINOOXYACETIC ACID,CBS,AGE RELATED OSTEOPOROSIS,"Pmcoa_2630375,Medline_18987302",TRUE,"The natural history of untreated CBS deficiency includes the development of venous thrombosis, arteriosclerosis, ectopia lentis, developmental delay, and osteoporosis [Mudd et al., 2001]","Medline_18940190,Medline_24145109,Medline_18201837,Pmcoa_4706096,Medline_23226735,Medline_25944997,Pmcoa_5904033,Medline_28383821,Medline_23063804,Pmcoa_3258007,Pmcoa_4372268,Medline_12160876,Pmcoa_4543995,Pmcoa_5131276,Patent_US20090214673,Pmcoa_4332225,Pmcoa_4741935,Pmcoa_3827285,Medline_16781459,Medline_21866187,Pmcoa_3875657,Pmcoa_4845716,Patent_US8092838,Medline_28713283,Pmcoa_4204999,Medline_24667534,Medline_27257787,Pmcoa_4658482,Medline_19255435,Pmcoa_3411702,Pmcoa_4372083,Pmcoa_5407269,Medline_23215842,Medline_25662313,Pmcoa_3493714,Medline_27440715",TRUE,infusion of the CBS inhibitors aminooxyacetic acid (10 mM) and hydroxylamine (20 mM) increased MAP but did not block the effects of infusion of 200 microM NaHS.,,keep
(S)-2-AMINO-4-PENTYNOIC ACID,CBS,AGE RELATED OSTEOPOROSIS,"Pmcoa_2630375,Medline_18987302",TRUE,,"Pmcoa_3469557,Medline_28847570",FALSE,"Furthermore, acetylcholine-induced relaxations were attenuated by cystathionine-gamma-lyase (CSE) inhibitor d,l-propargylglycine (PAG, 10-2 M) and cystathionine-β-synthase inhibitor (CBS) aminooxyacetic acid (AOAA, 10-3 M).",,keep
2-AMINO-2-HYDROXYACETIC ACID,CBS,AGE RELATED OSTEOPOROSIS,"Pmcoa_2630375,Medline_18987302",TRUE,,"Medline_23043860,Pmcoa_5411453,Medline_17101327,Patent_US20160095831,Pmcoa_5782486,Medline_28512446,Pmcoa_3144905,Patent_US20160095831A1",TRUE,"Importantly, all the beneficial effects of l-cysteine in SAH were abrogated by amino-oxyacetic acid, a CBS inhibitor. ",Molecular formula: C2H5NO3,new
CHYMOPAPAIN,CD34,AGE RELATED OSTEOPOROSIS,"Medline_22724005,Pmcoa_3377665,Pmcoa_4530234",TRUE,"Systemically delivered CD34(+) cells home to the bone marrow and significantly improve bone deposition, bone mineral density and bone micro-architecture in osteoporotic mice.","Medline_7488936,Medline_9217192,Medline_7514449,Patent_WO1996018639A1",TRUE,Using immunomagnetic beads (Isolex 300 SA. Baxter) CD34+ cells were enriched and released by chymopapain resulting in a median purity of 95% (range 82-99%) and a median recovery of 80% (range 27-132%).,,keep
POLOXAMER 407,CTSB,AGE RELATED OSTEOPOROSIS,"Medline_24881000,Patent_EP2353599A1,Patent_WO2011091973A1",TRUE,"Several cellular disorders have been related to the overexpression of the cysteine protease cathepsin B (CatB), such as rheumatic arthritis, muscular dystrophy, osteoporosis, Alzheimer's disease, and tumor metastasis. Therefore, inhibiting CatB may be a way to control unregulated cellular functions and prevent tissue malformations.","Pmcoa_3795317,Medline_23181274",TRUE,"Specifically, repeated P-407 administration over 4 months resulted in damage to endothelial cells and increased activity of cysteine protease cathepsin B and matrix metalloprotease (MMP) in heart tissue, which was associated with cardiomyocyte injury (Korolenko et al., 2012b).",,new
ALBENDAZOLE,CYP1A1,AGE RELATED OSTEOPOROSIS,"Medline_15647817,Medline_28300467",TRUE,"Our data, therefore, suggest that, through its effect on the rate of estrogen catabolism, the C4887A polymorphism of the CYP1A1 gene may represent a possible genetic risk factor for osteoporosis.","Medline_3404457,Pmcoa_3521711",TRUE,"On this regard, Bapiro et al. [54] demonstrated that quinine and albendazole induced CYP1A1 and CYP1A2 in HepG2 cells at concentrations equivalent to those achieved in therapeutic protocols alerting about the risk of combining quinine or albendazole with other drugs that are metabolized by these systems.",,keep
2-HYDROXYESTRADIOL,CYP1A1,AGE RELATED OSTEOPOROSIS,"Medline_15647817,Medline_28300467",TRUE,,"Medline_20881610,Pmcoa_4175619,Pmcoa_4313599",TRUE,"The vascular protective effects of estradiol are metabolized into 2-hydroxyestradiol (2HE) by CYP1A1, and 2HE is converted into 2-methoxyestradiol (2ME) by catechol-O-methyl transferase.",,new
ALOGLIPTIN,GIP,AGE RELATED OSTEOPOROSIS,"Medline_26642272,Patent_EP1119625A1,Patent_EP1119625B1,Patent_US20130137631,Patent_US6410508,Patent_US20130196913,Patent_US8895498,Patent_US20080312157,Patent_US20090036364,Patent_US20130281374,Patent_US8263545,Patent_US8404637,Patent_US9133260",TRUE,,"Patent_US20130059872,Medline_25227623,Pmcoa_4166248",TRUE,"Dipeptidyl peptidase-4 (DPP-4) inhibitors including alogliptin are categorised as a newer class of oral hypoglycaemic, antidiabetic drugs to suppress the degradation of incretin hormones ((glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP)) by DPP-4. ",,keep
NIMOTUZUMAB,IGFBP3,AGE RELATED OSTEOPOROSIS,"Pmcoa_4294440,Medline_25610822,Patent_US6518238,Patent_US6514937,Patent_WO1998036764A2,Patent_WO2000020024A2,Patent_WO2000006191A1",TRUE,A. japonica extract is increased to serum levels of IGFs and IGFBP-3 of osteoporosis induced by ovariectomized rats.,"Pmcoa_3540017,Medline_23232108",TRUE," In KYSE30 cell xenografts, Nimotuzumab combined with radiation led to significant tumor growth delay, compared with that of radiation alone (P=0.029), and also with IGFBP-3 up-regulation in tumor tissue.",,keep
MEGESTROL,MIR34A,AGE RELATED OSTEOPOROSIS,"Patent_US20160201056,Patent_WO2015026611A1,Pmcoa_4149606,Patent_WO2017050848A1,Medline_25043055,Pmcoa_5000714,Pmcoa_4600156,Pmcoa_5327426,Pmcoa_5349985,Pmcoa_5454890,Pmcoa_5547976",TRUE,"MiR-21 overexpression reversed osteoporosis by targeting RECK [8] and miR-34a prevented osteoporosis by inhibiting osteoclastogenesis via targeting Tgif2 [9]. Thus, microRNAs play important roles in bone development and skeletal disorders.","Patent_EP3160980A1,Patent_WO2015183667A1",FALSE,-,"Only patent references, impossible to proove it true or false.",new
UNII-WSU5343074,PPIA,AGE RELATED OSTEOPOROSIS,"Medline_26932182,Pmcoa_4774113",TRUE,"Thus, modulation of CypA activity may represent a novel option to regulate both osteoblast and osteoclast activity in order to combat osteoporotic bone loss.","Pmcoa_3185723,Medline_22585215,Pmcoa_3185663,Medline_19933795,Patent_US20160052972",TRUE,SCY-635 is also a non-immunosuppressive analogue of CsA that exerts potent anti-HCV activity in vitro.,,new
GESTODENE,SHBG,AGE RELATED OSTEOPOROSIS,"Medline_20452803,Pmcoa_4435629,Medline_27873076,Medline_22588185",TRUE,"Given that serum SHBG elevation is associated with the occurrence of multiple fractures, determination of the serum SHBG level, which can be readily performed in everyday clinical practice, may constitute a useful new marker for predicting the severity of osteoporosis.","Medline_1424621,Medline_8147246,Medline_7813219,Medline_8808163,Pmcoa_5721684",TRUE,"Thus, the present study showed that the pharmacokinetics of GEST can be fully explained on the basis of single dose pharmacokinetics and the changes in serum protein binding which were caused by a reduction of SHBG levels in the serum during chronic treatment with GEST. ",,new
ELIGLUSTAT,UGCG,AGE RELATED OSTEOPOROSIS,"Medline_11051736,Pmcoa_4358421",FALSE,"lucocorticoid use is the most common cause of iatrogenic and secondary osteoporosis. In a meta-analysis of seven cohort studies of 42,000 subjects, current and prior use of glucorticosteroids (GCSs) was found to be a predictor of the increased risk of fractures, independent of previous history of fractures and BMD.88","Patent_EP3253734A2,Patent_WO2016126572A2,Medline_26387627,Pmcoa_4927653,Pmcoa_4766994,Pmcoa_4226965,Pmcoa_4859014,Pmcoa_3126858,Patent_US20120202756,Pmcoa_2991350,Patent_WO2012046062A1,Pmcoa_3986510,Medline_17509920,Medline_20336375,Patent_WO2016209080A2,Pmcoa_4806476,Pmcoa_5355972,Medline_22058426,Pmcoa_3259697,Medline_26954668,Patent_US8961959,Patent_US20130095089,Patent_WO2013059119A1",-,,,new
CHLORDIAZEPOXIDE,TRH,ANKYLOSING SPONDYLARTHRITIDES,"Medline_7858584,Medline_8763085",FALSE,-,"Medline_3015558,Medline_6436800,Medline_2856406,Medline_8584022,Medline_2558307,Medline_8049715,Medline_2116028,Medline_6426979,Medline_2888647,Medline_2481818",-,,,keep
METHAPYRILENE,TRH,ANKYLOSING SPONDYLARTHRITIDES,"Medline_7858584,Medline_8763085",FALSE,,"Medline_12110379,Patent_EP1794182A2,Medline_2178251,Patent_EP1794182B1,Pmcoa_3777413,Medline_3093794,Patent_US7067257,Patent_US6475989,Patent_US20030232966,Patent_US7713935,Patent_WO2003089459A2,Patent_US20070265202",-,,,keep
PROTAMINE SULFATE,F10,ANTI PHOSPHOLIPID ANTIBODY SYNDROME,"Pmcoa_4365552,Medline_25864630,Medline_25890027,Medline_17114499,Medline_8578503",TRUE,Anti-FXa IgG were found in patients with SLE (49.1%) and APS (33.9%) (P <0.05) but not in ARD controls and HC,"Medline_1335615,Medline_1658966,Pmcoa_4969935,Medline_21297450",TRUE," Although the anti-Factor Xa effect of enoxaparin was incompletely neutralized by protamine sulfate in an experimental animal model, protamine sulfate reversed bleeding induced by hemorrhagic doses of enoxaparin.",,keep
GAMMA-CARBOXYGLUTAMIC ACID,F10,ANTI PHOSPHOLIPID ANTIBODY SYNDROME,"Pmcoa_4365552,Medline_25864630,Medline_25890027,Medline_17114499,Medline_8578503",TRUE,,"Patent_US20100255000,Patent_EP2453910B1,Patent_EP2414517B1,Patent_EP2193196B1,Patent_EP2364165B1,Patent_EP3078743A1,Patent_EP3121271A1,Patent_US20090098119,Patent_EP2915564A1,Patent_US20110015128,Patent_US20120269788,Patent_US20100125052,Patent_US20140134151,Patent_US20130129693,Patent_US20140044773,Patent_US20160002617,Patent_US20150025011,Patent_US20160354449,Patent_US20170233711,Patent_US20140079684,Patent_US20150057228,Patent_US9109046,Patent_US9023796,Patent_US9062298,Patent_US20170014492,Patent_US8455439,Patent_US8153590,Patent_US8268783,Patent_US8455441,Patent_US9056106,Patent_US9388401,Patent_US8889129,Patent_US9587233,Patent_EP2948168A1,Patent_WO2014116275A1,Patent_WO2009042962A2,Medline_417734,Medline_8119280,Medline_1989997,Medline_23455714,Patent_EP2305802A1,Patent_US20080004216,Patent_US20090280107,Patent_US20070066531,Patent_US20080026994,Patent_US20090281027,Patent_US20130172259,Patent_US20070225224,Patent_US20060264373,Patent_US20030100506,Patent_US20050075291,Patent_US20070161561,Patent_US20090275123,Patent_US20090280554,Patent_US20100311658,Patent_US20070225223,Patent_US7553934,Patent_US20140113330,Patent_US7314917,Patent_US7247708,Patent_US8642738,Patent_US7612188,Patent_US8415457,Patent_US8415458,Patent_US9266931,Patent_US8048990,Patent_US7479551,Patent_US7662923,Patent_US7553935,Patent_US7220837,Patent_US7750120,Pmcoa_5423471,Pmcoa_5874076",FALSE," We have isolated fragments, from tryptic digests of factor X, that consists of the gamma-carboxyglutamic acid (Gla) region linked to one or two epidermal growth factor (EGF)-like domains.",,keep
DABIGATRAN ETEXILATE,F10,ANTI PHOSPHOLIPID ANTIBODY SYNDROME,"Pmcoa_4365552,Medline_25864630,Medline_25890027,Medline_17114499,Medline_8578503",TRUE,,"Medline_23117667,Medline_19550318,Medline_23818798,Medline_23695644,Medline_21421599,Medline_22465061,Medline_24605405,Pmcoa_3693821,Pmcoa_4224738,Pmcoa_3228673,Pmcoa_3556861,Pmcoa_4132966",TRUE,"In daily practice, Dabigatran etexilate competes against the new direct factor Xa-inhibitors. ",,keep
BETRIXABAN,F10,ANTI PHOSPHOLIPID ANTIBODY SYNDROME,"Pmcoa_4365552,Medline_25864630,Medline_25890027,Medline_17114499,Medline_8578503",TRUE,,"Patent_US20150224091,Patent_US20080153876,Patent_US8404724,Patent_WO2013033370A1,Pmcoa_3283221,Pmcoa_3595681,Pmcoa_3743339,Pmcoa_4548753,Pmcoa_4428103,Pmcoa_3763648,Patent_EP2146705B1,Medline_19132191,Patent_EP2414517A1,Patent_EP2453910B1,Medline_23964817,Medline_29543384,Medline_27881569,Medline_29338293,Patent_EP2146705A2,Patent_EP2814955A1,Patent_EP2193196A2,Patent_EP2364165A2,Patent_EP2193196B1,Patent_EP2364165B1,Patent_EP2915564A1,Patent_EP3078743A1,Patent_EP3121271A1,Patent_EP2414517B1,Patent_EP2453910A1,Patent_US20100125052,Patent_EP2586439A1,Patent_US20080279845,Patent_US20110033459,Patent_US9062298,Patent_US20130230901,Patent_US20140079684,Patent_EP3254674A1,Patent_US20150057228,Patent_US20150376592,Patent_US20150025011,Patent_US20130129693,Patent_US20160002617,Patent_US20160354449,Patent_US20090098119,Patent_US20110015128,Patent_US20170014492,Patent_US20120095019,Patent_US20140044773,Patent_US20140134151,Patent_US20140323497,Patent_US20100255000,Patent_US20120269788,Patent_US9023796,Patent_US20170233711,Patent_US20170240879,Patent_US8153590,Patent_US8946219,Patent_US9587233,Patent_US8455441,Patent_US9388401,Patent_US9109046,Patent_US9056106,Patent_US8889129,Patent_WO2010056765A2,Patent_US8455439,Patent_WO2008137787A2,Patent_WO2010117729A1,Patent_US8268783,Patent_WO2013123087A1,Patent_WO2011008885A1,Patent_WO2009042962A2,Patent_WO2012031018A1,Pmcoa_3158856,Pmcoa_3782407,Pmcoa_4489817,Patent_WO2017211779A1,Pmcoa_4762436,Patent_EP1948608A2,Patent_EP1948608B1",TRUE,"Edoxaban and betrixaban, other factor Xa inhibitors, are in evaluation but not yet recommended by the FDA",,keep
XIMELAGATRAN,F10,ANTI PHOSPHOLIPID ANTIBODY SYNDROME,"Pmcoa_4365552,Medline_25864630,Medline_25890027,Medline_17114499,Medline_8578503",TRUE,,"Patent_EP2167487B1,Medline_12768805,Medline_26123214,Patent_EP2010534A1,Patent_US20080312311,Patent_US20090131459,Patent_US20090247555,Patent_US20100226918,Patent_EP1824855A1,Patent_EP2069365A1,Patent_EP2010535A1,Patent_EP2010535B1,Patent_EP2158202A1,Patent_EP1869056B1,Patent_EP2069364A1,Patent_EP1824855B1,Patent_EP2029598A1,Patent_EP2121020A2,Patent_EP1869056A1,Patent_EP2069364B1,Patent_EP1869055A1,Patent_EP2029603A1,Patent_US20090124637,Patent_US20090124640,Patent_US20080221136,Patent_US20080318981,Patent_US20110059996,Patent_US20100035899,Patent_US20080221133,Patent_US20100099642,Patent_US20080194527,Patent_US20090149475,Patent_US20080214578,Patent_US20090286813,Patent_US20120100204,Patent_US20150099769,Patent_US7960395,Patent_US20110092519,Patent_US20110105537,Patent_US7910576,Patent_US8859568,Patent_US7947693,Patent_WO2006062465A1,Patent_US7943625,Patent_US8088780,Patent_US9580429,Patent_WO2007142577A1,Patent_WO2008152420A1,Patent_US9440992,Patent_US8158785,Patent_US7829707,Patent_US8026244,Patent_WO2007142576A1,Patent_WO2008039138A1,Patent_WO2009120140A1,Patent_WO2006107258A1,Patent_WO2008039139A1,Patent_WO2008099144A2,Patent_WO2006107257A1,Patent_WO2016162785A1,Patent_WO2016162787A1",FALSE,"The new inhibitors of fibrin synthesis can be divided into direct thrombin inhibitors (hirudine, melagatran, ximelagatran), specific factor Xa inhibitors (pentasaccharides: fondaparinux, idraparinux) and inhibitors of the tissue thromboplastin factor VIIa complex (recombinant nematode anticoagulant protein c2, inactivated factor VIIa, recombinant tissue factor pathway inhibitor).",,keep
DAREXABAN,F10,ANTI PHOSPHOLIPID ANTIBODY SYNDROME,"Pmcoa_4365552,Medline_25864630,Medline_25890027,Medline_17114499,Medline_8578503",TRUE,,"Pmcoa_3295208,Medline_27121937,Medline_22031623,Pmcoa_5850258,Medline_22040919,Medline_22382330,Medline_23929659,Medline_25438755,Medline_22616561,Medline_23211396,Medline_23167531,Medline_23754514,Medline_21878434,Medline_22642721,Medline_23200896,Medline_27128609,Medline_23591155,Pmcoa_3283221",TRUE,"In conclusion, darexaban is a selective and direct factor Xa inhibitor and a promising oral anticoagulant for the prophylaxis and treatment of thromboembolic diseases.",,new
IDARUCIZUMAB,F10,ANTI PHOSPHOLIPID ANTIBODY SYNDROME,"Pmcoa_4365552,Medline_25864630,Medline_25890027,Medline_17114499,Medline_8578503",TRUE,,"Pmcoa_6058271,Pmcoa_4663607",FALSE,"Reversal agents for DOACs were initially lacking, but are currently under development (idarucizumab for dabigatran, and andexanet and PER977 for Fxa).",,new
GLYCINE AMIDE,ADAMTS5,ARTHRITIS,"Pmcoa_4289229,Pmcoa_4053306,Pmcoa_5074720,Pmcoa_5113859,Medline_21365186",TRUE,The plethora of emerging small-molecule ADAMTS aggrecanase inhibitors gives hope that some will be efficacious and tolerable and that those that are specific to ADAMTS5 could be developed as novel therapeutics for arthritis patients in the near future.,"Patent_US9695157,Patent_US20120041023,Patent_US20150210674,Medline_18974001,Patent_US9000009,Patent_US20170334890,Patent_EP3209794A1,Patent_WO2016061642A1",FALSE,N-((8-Hydroxy-5-substituted-quinolin-7-yl)(phenyl)methyl)-2-phenyloxy/amino-acetamide inhibitors of ADAMTS-5 (Aggrecanase-2) have been prepared.,,new
PBF-509,ADORA2A,ARTHRITIS,"Pmcoa_4609967,Medline_23283732,Pmcoa_5622197",TRUE,"In the present study, using two different mouse models of experimental arthritis, we addressed the role of the CD39/CD73 adenosinergic pathway and the contribution of the A2aR to the anti-inflammatory effects of exogenous treatment with FBP.","Pmcoa_5458644,Patent_WO2017023753A1",TRUE,Our studies showed that PBF-509 is highly specific to the A2aR as well as inhibitory of A2aR function in an in vitro model.,,keep
EVODENOSON,ADORA2A,ARTHRITIS,"Pmcoa_4609967,Medline_23283732,Pmcoa_5622197",TRUE,,"Patent_US20080312160A1,Medline_16622196,Pmcoa_2096525,Medline_19558673,Pmcoa_5476886,Pmcoa_2811859,Pmcoa_5522836,Pmcoa_3927137,Pmcoa_2711962,Pmcoa_3598653,Medline_20385073",TRUE,This study evaluated the effects of a new selective A2A adenosine receptor agonist (ATL 313) on toxin A-induced injury in murine ileal loops. ,,new
MLN 4760,ANG,ARTHRITIS,"Medline_12653852,Pmcoa_4997264,Medline_8724206,Pmcoa_5701946",TRUE,These data suggest that angiogenin may mediate local inflammation in arthritis via effects on angiogenesis and leucocyte regulation.,"Pmcoa_5641337,Medline_22318946,Patent_US20060257861",FALSE,The ACE2 inhibitor MLN-4760 and PCP/PEP inhibitor Z-pro-prolinal reduced cortical Ang-(1-7) formation.,,new
GR205171,B3GAT1,ARTHRITIS,"Medline_22687356,Pmcoa_17819",TRUE,"Because the expression of receptors on the primary afferent neurons is essential for the pain-producing action of inflammatory mediators and neuropeptides, we investigated in the present study whether the expression of BK and NK1 receptors on primary afferent neurons is altered during the acute and chronic phases of an antigen-induced arthritis (AIA)","Pmcoa_3796513,Pmcoa_1959516,Medline_11734064,Medline_18465582,Medline_10336675,Pmcoa_60651",FALSE,There is no evidence of NK1 receptors on peripheral nerve cells but the allocation of [11C]GR205171 may represent NK1 expression on non-neural cells such as immune and tissue cells.,,keep
NETUPITANT,B3GAT1,ARTHRITIS,"Medline_22687356,Pmcoa_17819",TRUE,,"Pmcoa_4282341,Patent_US20020091265,Patent_US6479483,Medline_25843024,Medline_22736506,Medline_25077526,Patent_WO2017147104A1",FALSE,"The aim of the present study was to investigate the pharmacological activity of Pronetupitant, a novel compound designed to act as prodrug of the NK1 antagonist Netupitant.",,keep
FOSAPREPITANT,B3GAT1,ARTHRITIS,"Medline_22687356,Pmcoa_17819",TRUE,,"Patent_US9782397,Pmcoa_5222820,Patent_EP2729147A1,Patent_US20140128395,Patent_WO2013004766A1,Patent_EP2729147B1,Pmcoa_4018359",FALSE,"On the day of the experiment, rats received cisplatin (0, 3, and 6 mg/kg, i.p.) with or without a daily injection of a 5-HT3 receptor antagonist (granisetron: 0.1 mg/kg, i.p.) or a neurokinin NK1 receptor antagonist (fosaprepitant: 2 mg/kg, i.p.), and their eye-opening index (the ratio between longitudinal and axial lengths of the eye) in the recorded video image was calculated.",,keep
MK 869,B3GAT1,ARTHRITIS,"Medline_22687356,Pmcoa_17819",TRUE,,"Patent_US20060019943,Patent_US20090030040,Patent_US8071778,Patent_US20090018132,Patent_US20090018163,Patent_US20080027056,Patent_US20090124613,Patent_US7098203,Patent_US8026257,Medline_12576885,Patent_US7632861",FALSE,"Furthermore, oral administration of the NK1 antagonists MK-869 (10 mg/kg), L-742694 (10 mg/kg), L-733060 (10 mg/kg), CP-99994 (30 mg/kg), and CP-122721 (3-30 mg/kg) reduced immobility time.",,keep
VESTIPITANT,B3GAT1,ARTHRITIS,"Medline_22687356,Pmcoa_17819",TRUE,,"Medline_24108409,Medline_20478677",FALSE,Vestipitant (1) is a novel NK1 antagonist currently under investigation for the treatment of CNS disorders and emesis. ,,keep
CHEMBL3126832,BIRC5,ARTHRITIS,"Pmcoa_4652986,Medline_17635796,Pmcoa_5428713,Pmcoa_4516528,Medline_25381389",TRUE,"This study demonstrates that intracellular expression of the oncoprotein survivin is a characteristic feature of Tfh cells in RA patients and in arthritic mice. The survivin positive subset of memory CD4 T cells possessed a complete signature of mature Tfh cells expressing CXCR5 and PD-1 receptors and master transcription factor Bcl-6 required for Tfh function [1, 22]. ","Medline_23900601,Medline_29752686",TRUE,"The co-treatment with OBP-801 and LY294002 markedly decreased survivin and the X-linked inhibitor of apoptosis protein (XIAP) protein levels, but Bcl-2 family members were not altered by the OBP-801/LY294002 co-treatment. ",,new
GATAPARSEN,BIRC5,ARTHRITIS,"Pmcoa_4652986,Medline_17635796,Pmcoa_5428713,Pmcoa_4516528,Medline_25381389",TRUE,,"Pmcoa_4224095,Medline_25436803,Pmcoa_5053666",TRUE,"Among several possible reasons, insufficient inhibition of survivin by LY2181308, an antisense oligonucleotide with limited in vivo bioavailability and uptake in tumors, may contribute to its disappointing clinical efficacy [46].",,new
ISATUXIMAB,CD38,ARTHRITIS,"Pmcoa_3306406,Pmcoa_4418770",TRUE,In the present study we explored whether the deficiency in CD38 influenced the clinical progression of CIA in B6 mice.,"Patent_EP3215541A1,Patent_WO2016071355A1,Medline_24987056,Pmcoa_5880931,Patent_WO2015123687A1,Patent_US20170049908,Patent_EP3104882A1,Patent_US20160346403,Pmcoa_5030378",TRUE,Isatuximab is a humanized IgG1 monoclonal antibody that binds to a specific epitope on the human CD38 receptor.,,keep
SALICYLHYDROXAMIC ACID,CYCS,ARTHRITIS,"Pmcoa_4951490,Pmcoa_4226164",TRUE,"The release of cytochrome c from mitochondria induces apoptosis, while its extracellular release initiates a DAMP response. Intra-articular injection of cytochrome c in mice induces arthritis (Pullerits et al., 2005).","Pmcoa_3463542,Pmcoa_4714917",FALSE,"Indeed, it has been suggested that SHAM might inhibit the cytochrome c oxidase (complex IV) [63], the terminal oxidase of the respiratory chain.","Both drug_gene_ref mention cytochrom c oxydase (COX), not cytochrome c itself.",new
ATOVAQUONE,CYCS,ARTHRITIS,"Pmcoa_4951490,Pmcoa_4226164",TRUE,,"Pmcoa_4566515,Pmcoa_4962491,Patent_US20140275088,Patent_US9873661,Patent_US09873661",TRUE,"Second, the reduction of cytochrome c is inhibited by atovaquone under conditions promoting complex III-dependent respiration in isolated mitochondria, but the reduction of dichlorophenolindophenol by complex II is not inhibited by atovaquone.","The drug ais used to treat malaria and it acts on the complex cytochrom bc of this parasite, but it has been tested for tumor (ref 2) and may act on cytochrome c in vitro.",new
REMOXIPRIDE,DRD2,ARTHRITIS,"Medline_26693483,Pmcoa_4677027",TRUE,Here we showed that lymphocyte DRD2 activation alleviates both imbalance of T-helper (Th)17/T-regulatory (Treg) cells and inflamed symptoms in a mouse arthritis model of RA. ,"Medline_24817271,Medline_15997230,Medline_10218872,Medline_7498321,Medline_8378244,Medline_7753765,Medline_8100193,Medline_1672458,Medline_11607043,Medline_7669486,Pmcoa_3602026,Medline_2895483,Patent_EP1578420A2,Patent_WO2004037783A2,Medline_21903866,Medline_9390726,Patent_US20080096926,Pmcoa_3893648,Pmcoa_4720788,Medline_1978494",TRUE,After oral administration of remoxipride 100 mg three times daily to a healthy male subject there was a 73% central D2-dopamine receptor occupancy. In a schizophrenic patient treated with remoxipride 200 mg twice daily there was a 71% occupancy,,keep
MECHLORETHAMINE HYDROCHLORIDE,DRD2,ARTHRITIS,"Medline_26693483,Pmcoa_4677027",TRUE,,"Medline_7820070,Patent_WO1997033550A2",FALSE,"The consequences of irreversibly-inhibiting D2 dopaminergic receptors on the expression of D1 and D2 dopamine receptor mRNAs and proenkephalin mRNA and on the levels of mu- and delta-opioid receptors in rat striatum were studied following single or repeated administration of the irreversibly-acting D2 dopamine receptor antagonist, fluphenazine-N-mustard (FNM).",,new
PROCHLORPERAZINE,DRD2,ARTHRITIS,"Medline_26693483,Pmcoa_4677027",TRUE,,"Patent_US20140066438A1,Patent_US20140066438,Medline_28853295,Medline_23064063,Pmcoa_5387065",TRUE,"Background Oral prochlorperazine, a dopamine D2 receptor antagonist, is largely metabolized to sulphoxide, 7-hydroxylate and N-desmethylate by cytochrome P450s (CYPs).",,new
AMISULPRIDE,DRD2,ARTHRITIS,"Medline_26693483,Pmcoa_4677027",TRUE,,"Patent_EP2732820A1,Patent_WO2008008433A2,Patent_WO2008127717A1,Patent_EP2038252A2,Patent_EP2136815A1,Patent_WO2008011073A2,Patent_WO2008024456A3,Patent_WO2008130571A1,Patent_EP2054049A2,Patent_US20110237664,Patent_EP2040709A2,Patent_US7772433,Patent_EP3147278A1,Patent_US8853266,Pmcoa_4726702,Pmcoa_3992878,Pmcoa_4755747",TRUE,"Furthermore, the short-arm phenotypic response to food was suppressed by antagonizing DRD2 with amisulpride, suggesting that dopamine functions downstream of algal sensation.",,new
TRIFLUOROPERAZINE DIHYDROCHLORIDE,DRD2,ARTHRITIS,"Medline_26693483,Pmcoa_4677027",TRUE,,"Medline_29066348,Medline_29580626",TRUE,We found that the dopamine receptor D2 antagonist trifluoperazine 2HCl inhibits growth and proliferation of GBM cells in a dose dependent manner.,Both references are “the same” (one is reprint of the other).,new
TIROFIBAN,DUSP2,ARTHRITIS,"Pmcoa_4222916,Pmcoa_5760626",TRUE,"Importantly, a lack of DUSP2 in immune cells suppresses the production of a variety of pro-inflammatory mediators in vitro [18] and reduces inflammation and disease pathology in a murine model of inflammatory arthritis [18].","Patent_US20150160213,Medline_16113794",TRUE,Tirofiban and eptifibatide inhibited massive platelet aggregation and PAC-1 binding which were induced by DHCA conditions.,,new
EPTIFIBATIDE,DUSP2,ARTHRITIS,"Pmcoa_4222916,Pmcoa_5760626",TRUE,,"Medline_16113794,Pmcoa_2812850",TRUE,Tirofiban and eptifibatide inhibited massive platelet aggregation and PAC-1 binding which were induced by DHCA conditions. ,"PMC reference is different, but Pubmed reference is the same as the one for tirofiban.",new
VORAPAXAR SULFATE,F2R,ARTHRITIS,"Pmcoa_3872103,Medline_15818676",TRUE,"Three of these members, PAR1, PAR3, and PAR4, are cleaved by thrombin, whereas PAR2 is cleaved by trypsin. The various physiological or pathogenic effects of thrombin are due to the widespread expression of thrombin receptors in many cells [15]. Increase in thrombin receptor mRNA in arthritis has been reported [16].","Pmcoa_3262324,Patent_US20080234236,Medline_19699853,Patent_US20160045506,Patent_US20170281710,Patent_WO2014152715A1,Pmcoa_3817733,Medline_20926621,Patent_EP2488026A1,Medline_20170841,Patent_EP2990051A1,Medline_19332592,Patent_EP2416799B1,Medline_21353434,Medline_19882073,Medline_21248619,Patent_US20170035734,Medline_18447380,Medline_21935705,Medline_21090833,Patent_US9789087,Patent_EP2990051B1,Patent_US20170065668,Patent_EP3061460A1,Patent_EP2440191A2,Patent_US20180000784,Patent_US20120141586,Patent_US20120121706,Patent_WO2010118435A2,Patent_WO2010144339A2,Patent_EP2416799A2,Patent_US20150023975,Pmcoa_2800923,Patent_US20120184504,Patent_WO2011041217A1,Patent_US9376499,Pmcoa_5545188,Patent_EP2134344A1,Patent_WO2008118320A1",TRUE,"SCH 530348 (also known as vorapaxar), an orally active, low-molecular weight, nonpeptide, competitive PAR-1 antagonist (tricyclic 3-phenylpyridine antagonist) potently inhibits thrombin-induced platelet aggregation without affecting measures of coagulation or increasing bleeding time.",,keep
DESMOPRESSIN ACETATE,F8,ARTHRITIS,"Medline_19781067,Pmcoa_2787264,Patent_EP1724286A1,Patent_US20090104202,Patent_US20060019340,Patent_US20090093053,Patent_US7534605,Patent_US20110207678,Patent_US8193311,Patent_US7883857,Patent_US7901909,Medline_29438784,Pmcoa_3978877",FALSE,"Following radioiodination, F8-IL10 was able to selectively target arthritic lesions and tumor neo-vascular structures in mice, as evidenced by autoradiographic analysis and quantitative biodistribution studies. ","Pmcoa_3030021,Pmcoa_3166073,Medline_9184393,Medline_8322282,Medline_8854570,Medline_25698197,Medline_8547104,Medline_2394244,Pmcoa_4834776",-,,,keep
DDAVP NASAL SPRAY,F8,ARTHRITIS,"Medline_19781067,Pmcoa_2787264,Patent_EP1724286A1,Patent_US20090104202,Patent_US20060019340,Patent_US20090093053,Patent_US7534605,Patent_US20110207678,Patent_US8193311,Patent_US7883857,Patent_US7901909,Medline_29438784,Pmcoa_3978877",FALSE,,"Medline_25698197,Pmcoa_4834776",-,,,keep
"ANTIHEMOPHILIC FACTOR (RECOMBINANT), PLASMA/ALBUMIN FREE METHOD",F8,ARTHRITIS,"Medline_19781067,Pmcoa_2787264,Patent_EP1724286A1,Patent_US20090104202,Patent_US20060019340,Patent_US20090093053,Patent_US7534605,Patent_US20110207678,Patent_US8193311,Patent_US7883857,Patent_US7901909,Medline_29438784,Pmcoa_3978877",FALSE,,"Pmcoa_4737295,Patent_EP2729161A2,Patent_WO2013009627A2",-,,,keep
ATOMOXETINE,FOS,ARTHRITIS,"Medline_20950869,Pmcoa_2976746,Medline_16437739",FALSE," In the adjuvant-induced arthritis Lewis rat model, we examined the dynamics of c-Fos expression in the hippocampus, a brain region important for these symptoms.","Medline_12431845,Patent_EP1458368B1,Patent_US20050009925,Patent_EP1458368A1,Patent_WO2005053663A2,Patent_WO2003049724A1,Medline_22119060",-,,,keep
CHEMBL444478,FOS,ARTHRITIS,"Medline_20950869,Pmcoa_2976746,Medline_16437739",FALSE,,"Pmcoa_3851776,Medline_24324641,Pmcoa_4560509",-,,,keep
POLYHISTIDINE,FOS,ARTHRITIS,"Medline_20950869,Pmcoa_2976746,Medline_16437739",FALSE,,"Patent_US20050159354,Patent_US20100095387,Pmcoa_2172957",-,,,keep
MEPYRAMINE,FOS,ARTHRITIS,"Medline_20950869,Pmcoa_2976746,Medline_16437739",FALSE,,"Medline_12925217,Medline_12873950",-,,,keep
ANAMORELIN HYDROCHLORIDE,GHSR,ARTHRITIS,"Medline_28636167,Medline_16030067",TRUE,Antagonists of ghrelin/growth hormone secretagogue receptor 1 (a subtype of cortistatin receptor) almost completely abolished the ameliorative effect of berberine on arthritis and Th17 cell responses in rats.,"Pmcoa_4248409,Pmcoa_3012235,Pmcoa_4538579,Medline_25267366",TRUE,"Based on these findings, the ghrelin receptor agonist anamorelin hydrochloride has recently been introduced for therapy of cancer-induced cachexia (currently in phase III clinical trials for treatment of cancer cachexia in non-small-cell lung cancer).",,new
DESERPIDINE,GSK3B,ARTHRITIS,"Pmcoa_2650783,Pmcoa_4277409",TRUE,"Importantly, GSK3β is central to the promotion of inflammation in various inflammatory diseases including colitis and arthritis","Pmcoa_5742885,Medline_25632187",FALSE,,,keep
CETIRIZINE,KNG1,ARTHRITIS,"Medline_11930961,Pmcoa_1781638,Patent_WO2007142431A1,Patent_US20150320761,Pmcoa_4421925",TRUE,Our previous results showed that nitric oxide (NO) and bradykinin (BK) mediate the arthritis induced by Bothrops jararaca venom (BjV) in rabbits.,"Medline_10782524,Medline_11003455,Medline_8886862,Medline_1362160",TRUE,"Moreover, cetirizine reduced significantly BK-induced wheals by 70% for IDT (P < 0.01) and 65% for PT (P < 0.01).","But also refering to BK, not KNG1",keep
INDAPAMIDE,KNG1,ARTHRITIS,"Medline_11930961,Pmcoa_1781638,Patent_WO2007142431A1,Patent_US20150320761,Pmcoa_4421925",TRUE,,"Medline_2109928,Medline_1656721",FALSE, The reduced relaxation to bradykinin was reversed in a concentration-dependent manner by indapamide (10(-7) to 10(-5) mol/liter).,,new
MERCAPTOPROPIONYLGLYCINE,KNG1,ARTHRITIS,"Medline_11930961,Pmcoa_1781638,Patent_WO2007142431A1,Patent_US20150320761,Pmcoa_4421925",TRUE,,"Pmcoa_2919536,Medline_20670410",FALSE,"Adenosine (80 ± 9% of baseline) and bradykinin (83 ± 4% of baseline) induced postconditioning (P < 0.0001 vs control), N-mercaptopropionylglycine abolished the beneficial effects of adenosine and bradykinin (54 ± 8 and 58 ± 5% of baseline, respectively).",,new
EMTRICITABINE,LTB4R,ARTHRITIS,"Pmcoa_2118298,Medline_16670336,Medline_20656922,Medline_29042029,Pmcoa_4502828,Patent_US20110059885",TRUE,"However, here we demonstrate a unique, non-redundant role for the leukotriene B4 receptor BLT1 in mediating neutrophil recruitment into the joint in the K/BxN mouse model of inflammatory arthritis","Pmcoa_3887103,Pmcoa_3380612,Pmcoa_2194746",FALSE,"We measured persistent HIV throughout the body during ART using bone marrow/liver/thymus (BLT) humanized mice, a model validated to study HIV persistence. HIV infected BLT mice were treated with tenofovir, emtricitabine and raltegravir.",,keep
GEDATOLISIB,MAP2K7,ARTHRITIS,"Pmcoa_3392838,Medline_28890347",TRUE,MKK7 plays a critical regulatory role in the JNK pathway in a murine model of arthritis.,"Pmcoa_4896852,Medline_22261591",FALSE,-,,keep
TRAMETINIB DIMETHYL SULFOXIDE,MAP2K7,ARTHRITIS,"Pmcoa_3392838,Medline_28890347",TRUE,,"Pmcoa_3681492,Clinicaltrial_NCT02281760,Pmcoa_6214970,Pmcoa_5438648,Medline_26200476,Patent_EP3331558A1,Pmcoa_5347684,Pmcoa_5737399,Patent_US20180228740,Patent_US20180228740A1,Medline_23237773,Pmcoa_6281416",TRUE,"Actually, JTP-74057/GSK1120212/trametinib has recently been demonstrated to be a first-in-MEK inhibitor able to improve the progression-free survival of BRAF-mutated advanced melanoma patients with its ideal pharmacological and pharmacokinetic profile.",,new
CHEMBL56564,MAPK14,ARTHRITIS,"Pmcoa_2235846,Pmcoa_1860061,Medline_28674435,Medline_22488549",TRUE,"Two of the 21 candidate genes were reported to be involved in arthritis. Mapk14, a candidate gene for locus 8 and also called p38 mitogen-activated protein kinase (MAPK) alpha, regulates the production of arthritis-essential cytokines, such as tumour necrosis factor and interleukin-1 [32]. ","Medline_22664143,Medline_23285267,Pmcoa_3532400",TRUE,"Additionally, we found that tropisetron prevents the phosphorylation and thus activation of the p38 MAPK, which is involved in post-transcriptional regulation of various cytokines.",,new
PYRIDINYLIMIDAZOLE,MAPK14,ARTHRITIS,"Pmcoa_2235846,Pmcoa_1860061,Medline_28674435,Medline_22488549",TRUE,,"Patent_WO2003093487A1,Medline_12127515,Patent_EP1112070B1,Patent_WO2000070030A1,Patent_EP1112070A1,Patent_US6589758,Patent_WO2002094842A2,Patent_EP2395004B1,Patent_US20130303534,Patent_US7863288,Patent_US20130261117,Patent_US20150290205,Patent_US8470818,Patent_EP1893612A1,Patent_WO2007002433A1,Patent_EP2395004A2,Patent_US8415469,Patent_US20100249118,Patent_US8143271,Patent_US20110059963,Patent_EP3088400A1,Patent_US20100256365,Patent_US20120022098,Patent_US20120053177,Medline_11459290,Patent_US20060105445",TRUE,"For the inhibition of p38 MAP kinase, pyridinylimidazole compound (SB203580) was utilized.",,new
ANGIOTENSIN 1-7,MAS1,ARTHRITIS,"Pmcoa_3272821,Pmcoa_4997264",TRUE,We have recently shown that Mas receptor activation decreased neutrophil migration and accumulation in models of arthritis,"Medline_28194766,Pmcoa_4582995,Pmcoa_4692500",TRUE,"A review of recent publications (2013-2016) on the rapidly progressing research on angiotensin 1-7 revealed that MAS1 and two additional receptors can function as 'angiotensin 1-7 receptors', and this deserves further consideration.",,keep
B 2050,NOS1,ARTHRITIS,"Pmcoa_4602262,Medline_16437739",TRUE,The total neuronal NOS (nNOS) levels were increased in muscles both from collagen-induced arthritis (CIA) mice and patients with RA.,"Medline_16023276,Medline_25046820,Patent_WO2010025266A1",FALSE,-,,keep
AC1LCVOZ,NOS1,ARTHRITIS,"Pmcoa_4602262,Medline_16437739",TRUE,,"Pmcoa_3190348,Medline_19103678,Pmcoa_2734311,Pmcoa_4488016",FALSE,-,,new
BENZENESULFONYL FLUORIDE,NPPB,ARTHRITIS,"Medline_23511225,Pmcoa_3963600",TRUE,A number of previous studies have shown that NT-pro-BNP concentrations are elevated in RA compared with population controls.26 27 Some of these have also noted an association between inflammation and NT-pro-BNP levels.25–27 ,"Patent_US20090215182,Patent_US9482677",FALSE,-,"Only patent references, impossible to proove it true or false.",new
ETORPHINE,OPRM1,ARTHRITIS,"Medline_27857662,Pmcoa_5109000",TRUE,(…) confirm the important role of spinal mOR in decreasing hyperalgesia during the chronic phase (arthritic phase) of AA. ,"Medline_15363980,Medline_2847851,Patent_EP1476155A2,Patent_US20040024005,Patent_WO2003061594A2,Medline_9450614,Medline_9350996,Medline_27707973,Medline_16417975,Medline_8799185,Medline_18599439,Pmcoa_4270172,Medline_8780231,Pmcoa_1947952,Medline_2986029,Medline_29183835,Medline_18930741",TRUE,"Taken together, these results suggest that etorphine-induced down-regulation may depend upon mu-opioid receptor degradation and changes in dynamin-2-mediated receptor trafficking.",,keep
TAPENTADOL,OPRM1,ARTHRITIS,"Medline_27857662,Pmcoa_5109000",TRUE,,"Pmcoa_5680940,Medline_24488603,Medline_29029015,Medline_21262850",TRUE,Tramadol and tapentadol combine these noradrenergic and serotonergic effects with mu opioid receptor activity. ,,keep
SUFENTANIL,OPRM1,ARTHRITIS,"Medline_27857662,Pmcoa_5109000",TRUE,,"Patent_EP1476155A2,Patent_US20040024005,Patent_WO2003061594A2,Medline_15780604,Medline_10781014,Medline_12044452,Medline_10497906,Medline_11299311,Medline_26342648,Patent_US20130158074,Patent_US8226978,Patent_US8535714,Patent_US8865743,Patent_EP3072504A1,Patent_US20080268023,Patent_US20090131479,Patent_US20130165481,Patent_US9744129,Patent_US20100105735,Patent_US20170259051,Patent_EP2114383B1,Patent_US20100256190,Patent_US8778394,Patent_US20100137836,Patent_US20120035216,Patent_US20130090594,Patent_US20140350054,Patent_US20160213606,Patent_US9642996,Patent_US20150105424,Patent_US9320710,Patent_US8778393,Patent_US8202535,Patent_US8231900",TRUE,"We have previously demonstrated that chronic and simultaneous treatment of rats with the mu-opioid receptor agonist sufentanil and the Ca(2+) channel blocker nimodipine, not only prevented tolerance development, but the animals became supersensitive to the antinociceptive effect of the opioid.",,keep
GSK-1521498,OPRM1,ARTHRITIS,"Medline_27857662,Pmcoa_5109000",TRUE,,"Medline_22752384,Medline_23934621,Pmcoa_3835938,Pmcoa_4282435,Pmcoa_3858811,Pmcoa_4537503",TRUE,"This study assessed the effects of 4-weeks of treatment with the MOR antagonist GSK1521498 on hedonic evaluation and consumption of food, binge-eating severity and body weight in obese people with binge-eating symptoms. ",,keep
TIANEPTINE,OPRM1,ARTHRITIS,"Medline_27857662,Pmcoa_5109000",TRUE,,"Medline_29073492,Patent_WO2017165738A1",TRUE,"Use of tianeptine, a mu-opioid receptor agonist was significantly associated with a lower risk of suicidal ideation worsening compared with other antidepressants in the first 6 weeks of treatment.",,keep
SAMIDORPHAN,OPRM1,ARTHRITIS,"Medline_27857662,Pmcoa_5109000",TRUE,,"Patent_US9283196,Patent_US20160031844,Patent_US9284291,Pmcoa_4679873",TRUE,"Perhaps the most compelling clinical data supporting antidepressant effects of KOR antagonists come from a recent study in which a combination of buprenorphine and the potent MOR antagonist samidorphan administered to subjects with treatment resistant MDD resulted in significant and substantial antidepressant activity without addictive potential (Ehrich et al., 2015).",,keep
MEROPENEM,OPRM1,ARTHRITIS,"Medline_27857662,Pmcoa_5109000",TRUE,,"Pmcoa_4519154,Pmcoa_5626926",FALSE," It should be mentioned here that the imipenem molecule itself is not exported by any of the efflux systems of P. aeruginosa while meropenem and doripenem are substrates for MexAB-OprM (Maseda et al., 2000; Masuda et al., 2000; Okamoto et al., 2002)",,keep
CARFENTANIL,OPRM1,ARTHRITIS,"Medline_27857662,Pmcoa_5109000",TRUE,,"Pmcoa_5754389,Medline_18762918,Medline_1965452,Pmcoa_4640219",TRUE,"In a study conducted by Jewett et al. [32], eight derivatives of [11C] carfentanil were evaluated as potential mOR agonists within the research for substances with better pharmacodynamics than the parent one.",,new
LEVALLORPHAN,OPRM1,ARTHRITIS,"Medline_27857662,Pmcoa_5109000",TRUE,,"Pmcoa_3189208,Patent_US20180153953,Patent_US20180153953A1",TRUE,"Fourth, nalbuphine, β-funaltrexamine and levallorphan were found to be partial agonists for the MOR. ",,new
LY2456302,OPRM1,ARTHRITIS,"Medline_27857662,Pmcoa_5109000",TRUE,,"Pmcoa_4368892,Patent_US20180153953,Patent_US20180153953A1",TRUE,"Because MOR antagonist activity may be observed at higher doses of LY2456302, the current study was designed to identify the dose at which LY2456302 produces MOR antagonism in healthy subjects, thus confirming that lower doses remain selective for KORs.",,new
DUVELISIB,PIK3CG,ARTHRITIS,"Medline_19734303,Patent_US20130267521,Patent_US20150111874,Patent_US20150105385,Patent_US20150225410,Patent_US9359365,Patent_US20170369511,Patent_US20170088553,Patent_US20160207940,Patent_US9751888,Patent_US9255108,Patent_US20160222016,Patent_US8940742,Patent_US9828377,Patent_WO2016054491A1,Patent_WO2017214269A1,Medline_16127437,Patent_EP2015752B1,Patent_EP2004654B1,Patent_US20130225629",TRUE,"Our data indicate that in addition to mediating the recruitment of inflammatory cells, PI3Kgamma is an important regulator of fibroblast-mediated joint destruction in RA and suggest that specific inhibitors of PI3Kgamma will interfere with the activation of RA synovial fibroblasts and reduce cartilage destruction in RA.","Medline_25258342,Pmcoa_4459446,Pmcoa_4197894",TRUE,"Of interest, the dual PI3K p110δ and p110γ inhibitor, IPI-145, also affects NK cells by promoting cell death [55].",,new
AS605240,PIK3CG,ARTHRITIS,"Medline_19734303,Patent_US20130267521,Patent_US20150111874,Patent_US20150105385,Patent_US20150225410,Patent_US9359365,Patent_US20170369511,Patent_US20170088553,Patent_US20160207940,Patent_US9751888,Patent_US9255108,Patent_US20160222016,Patent_US8940742,Patent_US9828377,Patent_WO2016054491A1,Patent_WO2017214269A1,Medline_16127437,Patent_EP2015752B1,Patent_EP2004654B1,Patent_US20130225629",TRUE,,"Pmcoa_3725284,Patent_US9512114,Patent_US9518046,Medline_18025236,Medline_19950590,Medline_20056919,Medline_19907415,Patent_US20160318914,Pmcoa_5777124,Medline_19494508,Pmcoa_2731529,Medline_21866628,Patent_US20160318913,Medline_22534961,Pmcoa_3425729,Patent_US9314485,Patent_US20100034786,Patent_EP2094837B1,Patent_US20150147304,Pmcoa_5220268",TRUE,"Importantly, selective inhibition of the p110γ isozyme of PI3K with AS605240 reduces adriamycin-mediated proteinuria and injury, suggesting that this kinase contributes to podocyte injury. ",,new
UPAMOSTAT,PLAU,ARTHRITIS,"Patent_US5444153,Patent_WO1991009124A1,Patent_US20030096733,Patent_WO2003033009A2,Pmcoa_154426,Medline_12716448,Pmcoa_4516528,Pmcoa_2991036,Pmcoa_2888184",TRUE,Accumulation of uPA locally in the joint cavity is a typical finding in erosive RA. uPA exerts potent arthritogenic properties and thus may be viewed as one of the essential mediators of joint inflammation.,"Pmcoa_3590684,Medline_23412098",TRUE,"Upamostat (WX-671) is the oral pro-drug of the active metabolite WX-UK1, a novel uPA inhibitor ",,new
UNOPROSTONE,PTGER2,ARTHRITIS,"Medline_16446378,Patent_US20150323528,Pmcoa_2118213,Patent_US9526782,Pmcoa_3859365,Patent_WO2017085198A1,Patent_WO2010009403A2,Pmcoa_3335257",TRUE,Inhibition of both PGE receptors (EP2 and EP4) suppressed inflammatory events and arthritis in CIA. These results suggest that both PGE2 and PGI2 participate in rheumatoid arthritis. ,"Patent_WO2011127064A2,Patent_EP2555749B1,Patent_US20130017243,Patent_US20160256382,Patent_US20150104491,Patent_EP2555749A2",FALSE,-,"Only patent references, impossible to proove it true or false.",new
TETRACAINE,RYR1,ARTHRITIS,"Pmcoa_5605300,Pmcoa_4602262",TRUE,"However, we have previously reported that the enhanced RyR1-mediated Ca2 + release was associated with a three-fold increase in the 3-NT levels on the RyR1 complex in skeletal muscle from mice with arthritis ","Pmcoa_2712967,Medline_19398777,Pmcoa_4141859",TRUE,"Finally, we confirmed that this passive efflux of calcium was blocked by tetracaine, an RYR1 antagonist [60], [61], revealing that the leak occurred via this receptor and was SR-derived [58], [62], [63].",,keep
ETHIODIZED OIL,SH2B2,ARTHRITIS,"Medline_8406862,Medline_1834576,Patent_US6159460,Medline_1428123,Medline_8513508,Medline_9214434",FALSE,Intraperitoneal (i.p.) injection of peptidoglycan-polysaccharide derived from group A streptococci (PG-APS) causes chronic arthritis with spontaneous remissions and exacerbations. ,"Pmcoa_5021746,Pmcoa_5331418",-,,,new
HYALURONIDASE RECOMBINANT HUMAN,TNFAIP6,ARTHRITIS,"Patent_US20160075750,Pmcoa_4721919,Pmcoa_165059,Medline_11696432,Patent_EP0567575B1,Patent_US20150355180,Patent_WO2014059178A1,Patent_EP1758607A1,Patent_US20070191269,Patent_WO2005060988A1",TRUE,"Also, administration of recombinant TSG-6 decreased experimentally-induced arthritis in several different models [28, 29]. ","Patent_US20140348817,Patent_US8846034,Patent_US20150218544,Patent_US9458442,Patent_US20130202583",FALSE,-,"Only patent references, impossible to proove it true or false.",new
ALDESLEUKIN,TNFRSF18,ARTHRITIS,"Pmcoa_3202109,Medline_27106763",TRUE,"Recent studies have shown that glucocorticoid-induced tumor necrosis factor-receptor-related protein (GITR) and its ligand (GITRL) are critically involved in the pathogenesis of autoimmune arthritis, but the role of GITRL/GITR signaling in modulating CD4(+) follicular helper T (Tfh) cell response during autoimmune arthritis remains largely unclear.","Pmcoa_5422719,Patent_WO2017033025A1",TRUE,Proleukin helped to maintain expression frequencies of CD137 and GITR on peripheral Treg over 18 h and promoted an increase in the frequency of OX40 expressing peripheral Treg. ,"The references mention superfamily of tumor necrosis factor receptor, but not specifically TNFRSF18 (one of the superfamilies).",new
VANILLIN,TRPV3,ARTHRITIS,"Pmcoa_4981835,Medline_27563416",TRUE,It seems that the hyperalgesia variation during different phases of CFA-induced arthritis correlates with spinal TRPV3 expression variation on peptidergic fibers. ,"Pmcoa_3804614,Pmcoa_2645550,Pmcoa_3792369,Pmcoa_4240255",TRUE,"Although vanillin was previously shown to activate TRPV3 at high concentrations [42][43], the concentrations used in our study are considerably lower. Therefore, we hypothesize that other channels may be modulated by this substance.",,new
EPA ETHYL ESTER,APOB,ASEPTIC NECROSIS OF BONE,"Pmcoa_4282735,Pmcoa_4247152,Medline_17530370",TRUE,"In 2007, Hirata et al. [14] found ApoB gene polymorphism was associated with osteonecrosis. ","Patent_WO2015066512A1,Patent_US20140357717,Pmcoa_5282870,Medline_22819432,Patent_US20160058729",TRUE,"Levels of apolipoprotein B (apoB) were significantly reduced with Vascepa 4 g/day in MARINE (P = 0.0019) and ANCHOR (P <0.0001) [7, 8].",,keep
PRAVASTATIN SODIUM,APOB,ASEPTIC NECROSIS OF BONE,"Pmcoa_4282735,Pmcoa_4247152,Medline_17530370",TRUE,,"Medline_3106756,Patent_US20060068015,Patent_EP1680086A2,Patent_US20050096390,Patent_WO2006037348A1,Patent_WO2005034908A2",TRUE,The fall in cholesterol was mainly due to a decrease in very-low-density lipoprotein (VLDL) and LDL cholesterol; high-density lipoprotein (HDL) cholesterol increased. Apolipoprotein B was reduced dramatically (by 21.7% to 30.5% with cholestyramine and 27.7% to 37.4% with pravastatin).,,keep
[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].CSCC[C@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](N)CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCNC(=O)[C@@H]1N=CC[C@H]1C)C(O)=O.COCCO[C@H]1[C@@H](O)[C@H](COP([O-])(=O)S[C@H]2[C@H](COP([O-])(=O)S[C@H]3[C@H](COP([O-])(=O)S[C@H]4[C@H](COP([O-])(=O)S[C@@H]5[C@@H](COP([O-])(=O)S[C@H]6C[C@@H](O[C@@H]6COP([O-])(=O)S[C@H]6C[C@@H](O[C@@H]6COP([O-])(=O)S[C@H]6C[C@@H](O[C@@H]6COP([O-])(=O)S[C@H]6C[C@@H](O[C@@H]6COP([O-])(=O)S[C@H]6C[C@@H](O[C@@H]6COP([O-])(=O)S[C@H]6C[C@@H](O[C@@H]6COP([O-])(=O)S[C@H]6C[C@@H](O[C@@H]6COP([O-])(=O)S[C@H]6C[C@@H](O[C@@H]6COP([O-])(=O)S[C@H]6C[C@@H](O[C@@H]6COP([O-])(=O)S[C@H]6C[C@@H](O[C@@H]6COP([O-])(=O)S[C@@H]6[C@@H](COP([O-])(=O)S[C@@H]7[C@@H](COP([O-])(=O)S[C@@H]8[C@@H](COP([O-])(=O)S[C@@H]9[C@@H](COP([O-])(=O)S[C@@H]%10[C@@H](CO)O[C@H]([C@@H]%10OCCOC)n%10cnc%11c%10nc(N)[nH]c%11=O)O[C@H]([C@@H]9OCCOC)n9cc(C)c(N)nc9,APOB,ASEPTIC NECROSIS OF BONE,"Pmcoa_4282735,Pmcoa_4247152,Medline_17530370",TRUE,,"Pmcoa_5090806,Pmcoa_4345304,Pmcoa_5341404",TRUE,"The second generation technology eventually led to the development of Kynamro®, a FDA-approved anti-apolipoprotein B (ApoB) AON for homozygous FH, in 2013 (discussed below).",The drug refered by the formula ir probably Mipomersen/Kynamro and the chemical formula will probably never be found. Should I change the Drug column?,new
FLUCLOXACILLIN,CYP3A,ASEPTIC NECROSIS OF BONE,"Medline_17787012,Medline_19997828",TRUE," Thus, suppression of CYP3A activity significantly increased vulnerability to steroid-induced osteonecrosis, while increased CYP3A activity reduced this vulnerability.","Medline_30447161,Pmcoa_6329626",TRUE,"Additionally, the strong inhibition in CYP3A‐catalysed flucloxacillin metabolism by sulfaphenazole suggests that unanticipated drug–drug interactions could occur with coadministered drugs.",,new
PLECONARIL,CYP3A,ASEPTIC NECROSIS OF BONE,"Medline_17787012,Medline_19997828",TRUE,,"Medline_16467135,Medline_16397289",TRUE, Observed changes in midazolam AUC(0-infinity) and systemic clearance suggest that oral pleconaril increased hepatic CYP3A activity in healthy adults.,,new
ATAZANAVIR,CYP3A,ASEPTIC NECROSIS OF BONE,"Medline_17787012,Medline_19997828",TRUE,,"Medline_15353575,Medline_24118434,Pmcoa_3857057,Clinicaltrial_NCT01772563",TRUE,"Similar to other PIs, atazanavir is metabolized by and inhibits CYP3A at clinically relevant concentrations; therefore, many potential drug interactions exist.",,new
POSACONAZOLE,CYP3A,ASEPTIC NECROSIS OF BONE,"Medline_17787012,Medline_19997828",TRUE,,"Pmcoa_3707037,Medline_29339097,Pmcoa_5315728,Pmcoa_5506877",TRUE,"Strong CYP 3A4 inhibitors include ketoconazole, voriconazole, posaconazole, and ritonavir.",,new
ANDROGRAPHIS,TRPV4,ASEPTIC NECROSIS OF BONE,"Pmcoa_5035228,Medline_27330106",TRUE,These findings identify a novel TRPV4 mutation implicating TRPV4 and altered calcium homeostasis in the pathogenesis of osteonecrosis while reinforcing the importance of TRPV4 in bone diseases and vascular endothelium.,"Pmcoa_2645550,Patent_EP3195857A1,Medline_16899456,Patent_US09693971,Patent_EP2879662B1,Patent_US20160128933A1,Patent_EP2879662A1",TRUE,"Very recently, a new TRPV4 agonist was identified. An extract from the plant Andrographis paniculata potently activate TRPV4 channels.",,new
COPANLISIB,ERBB2,BONE PAGET DISEASE,"Medline_21030863,Medline_20418225",FALSE,"In women, for instance, immunoexpression of c-erbB-2 favors a diagnosis of vulvar Paget disease, according to some studies. ","Pmcoa_5237710,Pmcoa_5225172,Medline_24170767",-,,,keep
ADO-TRASTUZUMAB EMTANSINE,ERBB2,BONE PAGET DISEASE,"Medline_21030863,Medline_20418225",FALSE,,"Pmcoa_4679405,Medline_26606967,Patent_WO2017087280A1,Patent_US20100099109,Pmcoa_5704598,Patent_EP3237065A1,Medline_25873876,Pmcoa_4376930,Medline_25790739,Patent_EP2796424B1,Patent_EP2796424A1,Patent_US20150071913,Patent_US9713572,Pmcoa_4112050,Pmcoa_4229898,Pmcoa_3973200,Pmcoa_4876844,Medline_25976081,Patent_EP2640727B1,Patent_US20120121615,Patent_US20110165155,Patent_US20140044709,Patent_US20150265723,Patent_US20170202973,Pmcoa_3337408,Pmcoa_4346691,Pmcoa_4058749,Pmcoa_5084478,Pmcoa_4793192,Patent_WO2017177199A2,Medline_23783223,Medline_26892972,Medline_26172389,Pmcoa_4501549,Medline_24987913,Medline_27497829,Patent_EP2771295A1,Patent_EP2771295B1,Patent_US20130216742,Patent_US20150366756,Patent_US9474688,Patent_WO2013063275A1,Medline_20421541,Medline_26557900,Medline_25024070,Medline_28679774,Pmcoa_3669149,Pmcoa_4629048,Pmcoa_5187895,Pmcoa_5768410,Medline_27366963,Medline_21986845,Medline_25342987,Medline_25332421,Medline_25865453,Medline_26389758,Medline_27572338,Medline_25398397,Pmcoa_5627411,Medline_29559276,Pmcoa_3502230,Medline_23402224,Medline_24043217,Medline_24662957,Medline_23946617,Medline_28056202,Medline_26917603,Patent_EP3107577A1,Patent_US20150132217,Patent_US20160361360,Patent_US20170035886,Patent_US20150231241,Patent_WO2015126548A1,Patent_WO2017007846A1,Patent_WO2017147542A2,Patent_WO2016141169A1,Patent_WO2016196373A2,Pmcoa_4596905,Pmcoa_5455677,Pmcoa_5278255,Medline_24035823,Medline_24898067,Pmcoa_4058446,Patent_US20170136043,Patent_US20150291605,Patent_US20150290197,Patent_US20150291606,Patent_US20150290212,Patent_US9555031,Patent_US20150291609,Patent_US20170202847,Patent_US9555030,Patent_WO2015157128A1,Patent_US9603850,Patent_WO2015153978A1,Patent_WO2015157115A1,Patent_WO2015157127A1,Patent_WO2015157123A1,Patent_WO2015157122A1,Patent_WO2015157125A1,Pmcoa_4596896,Pmcoa_5578078",-,,,keep
MM-302,ERBB2,BONE PAGET DISEASE,"Medline_21030863,Medline_20418225",FALSE,,"Medline_26759238,Patent_WO2017136770A1,Patent_EP2925361A1,Patent_US20170189335,Patent_US20160038416,Patent_US20160038417,Patent_US9226966,Patent_US9610249",-,,,keep
CP 724714,ERBB2,BONE PAGET DISEASE,"Medline_21030863,Medline_20418225",FALSE,,"Medline_28902361,Patent_EP2968564A1,Patent_US20050119288,Patent_US20080119530,Patent_US20160376376,Patent_US20150315244,Patent_US20160022680,Patent_US9303069,Patent_WO2014142660A1,Pmcoa_5831215,Pmcoa_5592866,Pmcoa_5882317",-,,,keep
TRAST,ERBB2,BONE PAGET DISEASE,"Medline_21030863,Medline_20418225",FALSE,,"Pmcoa_4891060,Patent_WO2016193955A1,Pmcoa_4891137,Pmcoa_3218942",-,,,keep
PATRITUMAB,ERBB2,BONE PAGET DISEASE,"Medline_21030863,Medline_20418225",FALSE,,"Pmcoa_4484825,Pmcoa_5084669,Pmcoa_4323007,Medline_25474137,Pmcoa_5117489",-,,,new
IMETELSTAT SODIUM,ERBB2,BONE PAGET DISEASE,"Medline_21030863,Medline_20418225",FALSE,,"Medline_18853252,Medline_25627551",-,,,new
IOPAMIDOL,BAX,CHRONIC ULCERATIVE COLITIS,"Medline_11413108,Medline_17629044",FALSE,Bcl-2/Bax system does not appear to be involved in the induction of apoptosis in UC.,"Pmcoa_5364980,Medline_28260077",-,,,keep
ATRACURIUM,BAX,CHRONIC ULCERATIVE COLITIS,"Medline_11413108,Medline_17629044",FALSE,,"Medline_27729798,Pmcoa_5042291",-,,,keep
HYDROXYMETHYLFURFURAL,BAX,CHRONIC ULCERATIVE COLITIS,"Medline_11413108,Medline_17629044",FALSE,,"Pmcoa_4846015,Pmcoa_4146024",-,,,keep
ISOVALERATE,BAX,CHRONIC ULCERATIVE COLITIS,"Medline_11413108,Medline_17629044",FALSE,,"Patent_EP2658535A1,Patent_WO2012092035A1",-,,"Only patent references, impossible to proove it true or false.",new
OXIDIZED ASCORBATE,BAX,CHRONIC ULCERATIVE COLITIS,"Medline_11413108,Medline_17629044",FALSE,,"Pmcoa_4363333,Medline_29644528",-,,,new
TAUROLIDINE,BAX,CHRONIC ULCERATIVE COLITIS,"Medline_11413108,Medline_17629044",FALSE,,"Pmcoa_3852505,Pmcoa_3551657,Pmcoa_3816653",-,,,new
DECANOATE,BAX,CHRONIC ULCERATIVE COLITIS,"Medline_11413108,Medline_17629044",FALSE,,"Medline_19857057,Medline_24335837,Pmcoa_4075746",-,,,new
MIMOSINE,CCND1,CHRONIC ULCERATIVE COLITIS,"Medline_12827612,Patent_US20140031389,Patent_US20100285002",FALSE,It is unclear whether and how cyclin D1 and/or p21(WAF1/CIP1) dysregulation contribute to ulcerative colitis (UC)-related inflammation and colorectal carcinogenesis. ,"Medline_10995875,Medline_10530763",-,,,keep
RONICICLIB,CCND1,CHRONIC ULCERATIVE COLITIS,"Medline_12827612,Patent_US20140031389,Patent_US20100285002",FALSE,,"Pmcoa_5427913,Patent_US20180163178",-,,,keep
VISMODEGIB,CCND1,CHRONIC ULCERATIVE COLITIS,"Medline_12827612,Patent_US20140031389,Patent_US20100285002",FALSE,,"Pmcoa_3975838,Pmcoa_5801594,Patent_EP2473522B1,Patent_US09910050,Patent_US9910050",-,,,new
CIS-UROCANIC ACID,CLDN1,CHRONIC ULCERATIVE COLITIS,"Pmcoa_5602518,Medline_20871038",FALSE,,"Patent_US20140086977,Patent_EP2691090A2,Patent_WO2012131341A2",-,,"Only patent references, impossible to proove it true or false.",new
UNII-88928BS57E,CXCL2,CHRONIC ULCERATIVE COLITIS,"Pmcoa_2644704,Medline_23272179,Pmcoa_3525572,Pmcoa_4812449",TRUE,"From our data, we conclude that real-time PCR quantification of CXCL8, CXCL10, calgranulin B and CXCL2 in colonic biopsies is a simple and objective method for grading inflammation of intestinal mucosa in UC.","Medline_28749086,Pmcoa_5722510",TRUE,"Pretreatment with PLAG reduced the levels of interleukin (IL)-4, IL-6, IL-10, and CXCL2, but maintained interferon (IFN)-γ levels and modulated neutrophil recruitment toward the liver.",UNII-… is also called EC-18,keep
LY-2874455,FGFR1,CHRONIC ULCERATIVE COLITIS,"Medline_28928792,Pmcoa_5591922",TRUE,"Garidisan elevated EGF, VEGF, bFGF, VEGFR2, and FGFR1 of UC rats, reduced CD3+CD4+/CD3+CD8+ T cell ratios, and increased CD4+Th1/CD4+Th2 cell ratios and IFN-r/IL-4 ratios in peripheral blood of UC rats","Pmcoa_5019380,Medline_27618313",TRUE,"Consequently, our studies reveal new insights into the pan-FGFR selectivity of LY2874455 and provide a structural basis for developing novel FGFR inhibitors that target FGFR1-4 broadly.",,keep
VX 950,KRAS,CHRONIC ULCERATIVE COLITIS,"Medline_2194896,Medline_1854618,Pmcoa_1977292,Medline_1350261",TRUE,This lower prevalence rate and different site distribution of c-Ki-ras mutations in UC carcinomas compared to sporadic carcinomas suggests that specific genetic differences may underlie the causation of carcinomas arising in these situations.,"Patent_EP1678202A1,Patent_EP1678202B1,Patent_WO2005042570A1,Patent_US20080267915,Medline_19505593,Patent_US20110243894,Patent_US20100074890,Patent_US20110008289,Patent_US20110110891,Patent_WO2005110455A2,Patent_WO2006016930A2,Patent_US8603737,Patent_EP2054076A2,Patent_WO2011049987A2,Patent_EP1987060A2,Patent_EP1789074A2,Patent_EP2491033A2,Patent_US20180000926,Patent_EP3244922A1,Patent_US20100093824,Patent_US20070258946,Patent_US20060204473,Patent_US20080131398,Patent_WO2006020580A2,Patent_EP2341924A2,Patent_US7597884,Patent_US20060182716,Patent_US20150098926,Patent_US20130195798,Patent_WO2010081095A2,Patent_WO2016112459A1,Patent_WO2005067963A1,Patent_WO2008143647A2,Patent_WO2007092537A2,Patent_WO2010039801A2,Patent_EP2500021A1,Patent_EP2157974A1,Patent_US20060105978,Patent_EP2328656A1,Patent_WO2006050250A2,Patent_EP1819336A2,Patent_US20100189688,Patent_US20110236351,Patent_WO2010036799A1,Patent_US8871812,Patent_WO2008144072A1,Patent_EP1804821A2,Patent_EP2374464A2,Patent_WO2006039488A2,Patent_US20110059886,Pmcoa_3861371,Patent_US7884199,Patent_US20090191555,Patent_US20100028874,Patent_US20050136400,Patent_EP2016195A2,Patent_US20110086006,Patent_US7494660,Patent_US20090004664",FALSE,"We tested the effect of VX950, a specific inhibitor of NS3/4A protease, on C4 cleavage by NS3/4A protease and inhibition of complement activation. ",,keep
RILOTUMUMAB,KRAS,CHRONIC ULCERATIVE COLITIS,"Medline_2194896,Medline_1854618,Pmcoa_1977292,Medline_1350261",TRUE,,"Pmcoa_4037834,Pmcoa_5344276",FALSE,"Recently, phase I and II trials of HGF-targeted monoclonal antibodies, such as TAK701, AMG102 (rilotumumab) and SCH900105 (AV299), have been carried out in solid tumours (Meetze et al, 2009). A phase II randomised trial that compared rilotumumab or ganitumab (AMG 479) with panitumumab vs panitumumab alone in KRAS wild-type patients with mCRC revealed that the arm with rilotumumab achieved better response and PFS compared with panitumumab alone (Eng et al, 2011). ",,keep
RACECADOTRIL,MME,CHRONIC ULCERATIVE COLITIS,"Medline_29232715,Pmcoa_5726735",TRUE,Concurrent decreases in SP and VIP with profound loss of NEP expression observed in UC is likely to be one of the factors in pathogenesis.,"Pmcoa_3362754,Pmcoa_4851326,Medline_12106279,Medline_1421123,Medline_7473405,Patent_US20150342882,Patent_US20160120834,Patent_WO2017026994A1,Medline_26731112,Medline_3519939,Medline_3554169,Medline_7509244,Medline_19300128,Medline_1376694,Medline_1780043,Medline_10646048,Medline_10944563,Medline_2716968,Medline_2702924,Medline_27642742,Medline_2790459,Medline_3532054,Medline_2142087,Patent_WO2016066758A1,Medline_2018165,Medline_1624154,Medline_10717503,Medline_1285638,Medline_10646045,Medline_1350927,Medline_1666049,Medline_26907621,Medline_1348542,Medline_2142086,Medline_1788138,Medline_8804878,Patent_EP1718337B1,Medline_3131801,Medline_19610134,Medline_10717505,Medline_22661949,Patent_EP1563848A1,Medline_27209450,Medline_9355786,Medline_2780419,Medline_3121843,Medline_2612837,Medline_2758762,Patent_US20070275993,Medline_8488368,Patent_EP1718337A1,Patent_US8222294,Patent_EP3212211A1,Patent_WO1989005353A1,Pmcoa_3694821,Patent_WO2005079850A1,Pmcoa_3875871,Pmcoa_3085874,Patent_WO2015160703A1,Patent_WO1991001756A1,Pmcoa_3561631,Pmcoa_4695804",TRUE,"n conclusion, racecadotril and its metabolite acetyl-thiorphan are only low potency NEP inhibitors. However, racecadotril is rapidly converted to the active metabolite thiorphan in vitro (Lecomte et al., 1986) and in vivo (see Pharmacokinetic and Drug–Drug Interaction Studies), and thiorphan is an about 1000 times more potent NEP inhibitor than racecadotril with reported potencies of 0.4–9 nM.",Most of the references mention the drug related to Enkephalinase; MME is one of the subtypes of those enzymes.,keep
TEMOCAPRIL,MME,CHRONIC ULCERATIVE COLITIS,"Medline_29232715,Pmcoa_5726735",TRUE,,"Patent_EP2665701A2,Patent_US20100311800,Patent_WO2011100384A1,Patent_WO2012122077A1,Patent_EP2250168B1,Patent_EP2498605B1,Patent_EP2683687B1,Patent_EP2244575B1,Patent_EP2225225A2,Patent_EP2250158A2,Patent_EP2485734B1,Patent_EP2250168A2,Patent_EP2291076A1,Patent_EP2326652B1,Patent_EP2369924A1,Patent_EP2373630A1,Patent_EP2571351A1,Patent_EP2632255B1,Patent_EP2533644A1,Patent_US20100029678,Patent_EP2121664A2,Patent_EP1874302A1,Patent_EP2313417A1,Patent_EP2121665A2,Patent_EP2244575A1,Patent_EP2121664B1,Patent_EP2533644B1,Patent_US20100144810,Patent_US20120208838,Patent_US20110160229,Patent_US20110230532,Patent_EP2121665B1,Patent_EP2498605A1,Patent_US20130053352,Patent_EP2334179A1,Patent_EP2326652A1,Patent_EP2369924B1,Patent_EP2571351B1,Patent_EP2632255A1,Patent_EP2704568A1,Patent_US8252825,Patent_US20090123538,Patent_US20100273845,Patent_US20100298277,Patent_US20100305135,Patent_US7947664,Patent_US8354394,Patent_US8361994,Patent_US20130059823,Patent_US20140088048,Patent_US8053455,Patent_US20100152259,Patent_US20100292192,Patent_US20120238608,Patent_US20130296278,Patent_US20080194660,Patent_US20100152258,Patent_US20110065765,Patent_US8329697,Patent_US8629275,Patent_US9108920,Patent_EP2257161B1,Patent_EP2485734A1,Patent_EP2683687A1,Patent_US20110201621,Patent_US8367711,Patent_US8623846,Patent_US20120232039,Patent_US9272987,Patent_US7834042,Patent_WO2009099853A2,Patent_WO2009106470A2,Patent_WO2010027935A1,Patent_WO2012151114A1,Patent_WO2009070241A2,Patent_WO2011146371A1,Patent_US20110077279,Patent_US20130289003,Patent_US7880014,Patent_US8293777,Patent_US8648058,Patent_WO2012099770A2,Patent_WO2010015447A1,Patent_WO2010062415A1,Patent_WO2011053519A1,Patent_WO2012058203A1,Patent_US8106034,Patent_US8119806,Patent_US8207208,Patent_US8530521,Patent_US20120202845,Patent_WO2010014516A1,Patent_US8377911,Patent_WO2009150007A1,Patent_WO2008076246A2,Patent_WO2009094242A1,Patent_WO2011043914A1,Patent_WO2010065432A1,Patent_WO2006115834A1,Patent_WO2008076245A2,Patent_WO2009140111A1,Medline_15897363",FALSE,"The hypertensive rats were randomized into groups that received no treatment or were treated with an ACE inhibitor (temocapril), an ECE/NEP inhibitor (CGS 26303), or a NEP inhibitor (CGS 24592) from the LVH stage (11 weeks) to the CHF stage (17 weeks).",,new
CANDOXATRILAT,MME,CHRONIC ULCERATIVE COLITIS,"Medline_29232715,Pmcoa_5726735",TRUE,,"Patent_US20050261179,Patent_EP1545287A2,Patent_WO2004032708A2,Patent_EP1545287B1,Patent_US7364719,Medline_16821800,Patent_WO2007003594A1,Patent_WO2004056787A1,Medline_12941780,Medline_10595958,Patent_EP1581480A1,Patent_US20050075392,Medline_18725584,Medline_9639376,Patent_EP1578735A1,Patent_US8993631,Pmcoa_4869613,Patent_US7045653,Medline_29591681,Patent_WO2012065958A1,Medline_12354448,Patent_US20120122844,Patent_US20140336194,Patent_EP2640375A1,Pmcoa_3181606,Patent_WO2004056750A1,Pmcoa_2643003,Medline_9729514,Patent_EP1581480B1,Patent_US20040138274",TRUE,The neutral endopeptidase inhibitor candoxatrilat (5 mg/kg per day IV for 7 to 9 days) restored vagal reflex bradycardia in old rats (n=6) to levels similar to those in young neutral endopeptidase inhibitor-treated rats (n=6).,,new
GUANFACINE,ARSD,CROHN'S DISEASE,"Patent_US9050276,Patent_US20120207726,Pmcoa_5073317,Patent_WO2017172521A1",FALSE,"We have previously reported the molecular profile for histological ASD-associated ileocolitis that confirms, at the level of gene expression, the presence of ASD-associated IBD and discriminates it from Crohn’s disease and ulcerative colitis19.","Pmcoa_5789216,Patent_US20170348417,Patent_WO2014168820A1,Patent_EP2983652A1,Pmcoa_3420490",FALSE,,,new
TOLBUTAMIDE,GAST,CROHN'S DISEASE,"Medline_28443771,Patent_EP2010569A2,Patent_US20090311257,Patent_US8278421,Patent_WO2007111661A2,Medline_12795463",TRUE,Gastrin release in response to bombesin decreases in patients with Crohn disease treated with infliximab.,"Medline_3065196,Medline_6642411",TRUE,"Thus, our data suggest that tolbutamide inhibits gastrin release in man via mechanisms independent of changes in plasma insulin, blood glucose or acid secretion.",,keep
METIAMIDA,GAST,CROHN'S DISEASE,"Medline_28443771,Patent_EP2010569A2,Patent_US20090311257,Patent_US8278421,Patent_WO2007111661A2,Medline_12795463",TRUE,,"Medline_1686922,Medline_11029,Medline_437421,Medline_184871",TRUE,"It is concluded that in spite of rises in serum gastrin, prolonged metiamide medication has no effect on the gastrin content of the antrum and gastric corpus nor on the G-cell population in the rat. Furthermore, after prolonged treatment, metiamide-induced gastrin release is diminished.",,keep
HOMOSERINE LACTONE,GLS,CROHN'S DISEASE,"Medline_17078002,Medline_15735434,Patent_EP3048904A2,Patent_US20160317614",TRUE,We analyzed the systemic and intestinal glutamine status in Crohn's disease (CD) and evaluated the therapeutic effect of glutamine supplementation in an animal model of ileitis.,"Pmcoa_5442451,Medline_28536283",FALSE,-,,new
AT7519,MCL1,CROHN'S DISEASE,"Medline_18266233,Medline_28190086",TRUE,"Finally, immunohistochemistry showed reduced MCL-1 protein expression in fibrotic CD samples compared to non-stricturing controls. ","Pmcoa_4891027,Pmcoa_3940382",TRUE,"We first confirmed that AT7519 induced rapid down-regulation of MCL1 mRNA (Figure 5A and 5B), and then used siRNA to suppress its expression in MCF-7 cells (Figure ​(Figure5C).5C).",,keep
CRYSTAL VIOLET SOLUTION,NOX1,CROHN'S DISEASE,"Medline_24374371,Pmcoa_5148781,Pmcoa_4943970",FALSE,"DUOX2 and NOX1 variants are associated with VEO-IBD patients who demonstrate lower activity than healthy controls [62]. However, DUOX2 and DUOXA2 expression were induced up to 16- and 52-fold, respectively, in pediatric and adult Crohn's disease patients","Pmcoa_3977805,Pmcoa_5651112",-,,,keep
ENTOLIMOD,TLR5,CROHN'S DISEASE,"Medline_16319670,Medline_28139755,Medline_16439468",TRUE,Our results suggest that SNPs associated with genetically determined high activity of TLR5 among patients with CD and genetically determined high IL-12 and IL-18 levels among patients with UC were associated with non-response,"Patent_US9376473,Patent_US20170065692,Medline_28407032,Medline_24583651,Patent_US20140248260,Pmcoa_5825991,Patent_EP2833876A1,Patent_WO2013151994A1,Pmcoa_3314012,Medline_24879439,Pmcoa_5385203,Medline_28273362,Pmcoa_3674368,Pmcoa_5126092,Medline_24454895,Pmcoa_3823175,Pmcoa_5737079,Pmcoa_5799711,Patent_WO2014098649A1,Pmcoa_3891810,Pmcoa_4823082,Pmcoa_4998329,Medline_26655090,Pmcoa_3782517,Pmcoa_3996654,Pmcoa_5628280,Patent_EP3206708A2,Patent_US20170239326,Patent_WO2016109002A2,Pmcoa_4418776,Pmcoa_4569586,Medline_28323577,Pmcoa_4039429,Medline_26367124,Pmcoa_5689665",TRUE,The method developed here could be an effective in vitro system to screen other TLR5-target radioprotectants like CBLB502.,,keep
MOMETASONE,HPSE,FIBROMYALGIA,"Patent_US20090081243,Patent_EP2527446A1,Patent_US20150322517,Patent_EP2527447A1,Patent_EP1766014A1,Patent_EP2270034A2,Patent_WO2005118810A1,Medline_18158367,Pmcoa_416451,Patent_US20130034537,Pmcoa_416440",FALSE,Chronic pelvic pain (CPP) and fibromyalgia syndrome (FMS) have been associated with hypothalamic-pituitary-adrenal (HPA) axis alterations,"Medline_22409907,Pmcoa_3339360",-,,,keep
GLUCURONIC ACID,HPSE,FIBROMYALGIA,"Patent_US20090081243,Patent_EP2527446A1,Patent_US20150322517,Patent_EP2527447A1,Patent_EP1766014A1,Patent_EP2270034A2,Patent_WO2005118810A1,Medline_18158367,Pmcoa_416451,Patent_US20130034537,Pmcoa_416440",FALSE,,"Medline_26062789,Medline_15647251",-,,,new
CISATRACURIUM,MAP1LC3A,FIBROMYALGIA,"Medline_26772544,Pmcoa_4715288",FALSE,"Their answers to the set of FM-symptom questions in 1990 classified them in three latent classes (LC): LC1 with no or few symptoms, LC2 with some symptoms, and LC3 with many FM symptoms.","Medline_27058536,Pmcoa_4848971",-,,,keep
GLYCERALDEHYDE 3 PHOSPHATE,TKT,FIBROMYALGIA,"Pmcoa_1876608,Medline_2407767",TRUE,Fifty patients with abnormal transketolase activity coefficient (ETK-AC) and affinity for coenzyme (Km-TPP) had associated fibromyalgia or senile dementia of Alzheimer type (20).,"Medline_24456572,Pmcoa_317351",FALSE,,,keep
GLYCERALDEHYDE-3-PHOSPHATE,TKT,FIBROMYALGIA,"Pmcoa_1876608,Medline_2407767",TRUE,,"Pmcoa_4580311,Pmcoa_2690845,Patent_US20080234304A1,Patent_US20080234304",FALSE,,,new
SULBACTAM,CD248,GRANULOMATOSIS WITH POLYANGIITIS,"Medline_28615072,Pmcoa_5471953",FALSE,Chemokine receptor co-expression analysis within the CD4+ TEM cell population demonstrated a significant increase in the proportion of TEM17 cells with a concomitant significant decrease in the TEM1 cells in GPA patients compared to HC.,"Pmcoa_5036594,Medline_9527373,Pmcoa_5456380,Medline_7606585,Medline_9062788",-,,,keep
MORAB-004,CD248,GRANULOMATOSIS WITH POLYANGIITIS,"Medline_28615072,Pmcoa_5471953",FALSE,,"Pmcoa_4694842,Pmcoa_5124654,Pmcoa_4985356,Medline_26327620,Patent_EP2568044A1,Patent_US9290556,Patent_US20160331819,Patent_EP2568044B1,Patent_US20120035529",-,,,new
FERRIC CARBOXYMALTOSE,FGF23,KAWASAKI DISEASE,"Medline_24168888,Pmcoa_3832880",TRUE,The prevalent segregation of the c.212-37insC polymorphism in children with CaA advocates a possible functional FGF23 role in the predisposition to higher serum levels of FGF23 and potential occurrence of any coronary artery abnormalities in KS.,"Pmcoa_5353490,Pmcoa_5419608",TRUE,"Furthermore, ferric carboxymaltose may inhibit i-FGF23 degradation in osteocytes resulting in transiently increased i-FGF23 levels [21].",,new
LANTHANUM CARBONATE,FGF23,KAWASAKI DISEASE,"Medline_24168888,Pmcoa_3832880",TRUE,,"Medline_21436379,Pmcoa_4170220,Medline_24885942,Pmcoa_5509238,Pmcoa_3379863,Pmcoa_4107721",TRUE,"In conclusion, lanthanum carbonate reduced phosphate load, as assessed by urinary phosphate excretion, and also reduced plasma FGF23 in CKD-3 patients. ",,new
BUROSUMAB,FGF23,KAWASAKI DISEASE,"Medline_24168888,Pmcoa_3832880",TRUE,,"Pmcoa_5826173,Patent_US20150353633,Patent_EP3151859A1,Medline_29947083,Pmcoa_6223702,Medline_29679282,Pmcoa_6073187",TRUE,"Burosumab (Crysvita®), a fully human IgG1 monoclonal antibody directed at fibroblast growth factor 23 (FGF23), is indicated for the treatment of X-linked hypophosphatemia (XLH), a condition associated with excessive FGF23 production.",,new
C5H3N4O,EEF1A1,LYME DISEASE,"Medline_26954993,Pmcoa_5176084",FALSE,"We found that EF-Tu is highly immunogenic in mice, and EF-Tu antibodies were readily detected in Lyme disease patients.","Pmcoa_2896532,Pmcoa_5059743",-,,,keep
ZINC ACETATE,RAD51,LYME DISEASE,"Pmcoa_5663514,Medline_29088268,Patent_US20150232517,Patent_EP2889382A1,Medline_8566765,Patent_US20160289746,Patent_EP3044337A2,Patent_US20150250865,Patent_US20160333056",FALSE,"An enhanced need, relative to E. coli RecA, for sequestration of the displaced strand indicates that the reaction promoted by B. burgdorferi RecA is more prone to reversal if the displaced strand is not sequestered. Precedent for this role for a single-stranded DNA binding protein is found in studies with yeast RPA and Rad51 [36]","Pmcoa_4072484,Pmcoa_5440055",-,,,keep
D-TREITOL,RAD51,LYME DISEASE,"Pmcoa_5663514,Medline_29088268,Patent_US20150232517,Patent_EP2889382A1,Medline_8566765,Patent_US20160289746,Patent_EP3044337A2,Patent_US20150250865,Patent_US20160333056",FALSE,,"Patent_EP1874801A2,Patent_WO2009154828A2,Patent_WO2006096757A2",-,-,"Only patent references, impossible to proove it true or false.",new
NALIDIXIC ACID,TOP2A,LYME DISEASE,"Patent_US20030170693,Medline_10469665",FALSE,-,"Medline_7766118,Patent_EP2603601A2,Medline_16667857,Patent_US20130324437,Medline_7504668,Medline_2547335,Medline_1332615,Medline_2856355,Medline_3004325,Medline_12948384,Medline_8381639,Medline_2558950,Patent_WO2012021802A2,Pmcoa_5739488,Patent_US20110065092,Medline_15347763,Pmcoa_4029002,Patent_US5656495,Patent_EP2522738A1,Medline_6450709,Patent_EP0723018A1,Medline_2407187,Patent_EP0723018B1,Medline_26331851,Medline_3008718,Medline_20958788,Medline_2570350,Pmcoa_3711813,Patent_US8703447,Patent_WO2000037676A1,Pmcoa_3565448,Pmcoa_3874168,Pmcoa_4230183,Pmcoa_4270457,Pmcoa_2553793,Patent_US20120322115,Pmcoa_4558043,Medline_8097554,Pmcoa_3001019,Medline_28825963,Medline_200930,Pmcoa_1635304,Pmcoa_3312209,Pmcoa_4207537,Pmcoa_3769818",-,,,keep
DINITROBENZENE,HBG2,POLYCYTHEMIA,"Medline_1634355,Medline_5796352",FALSE,"Hemoglobin Rainier (beta(145) tyrosine-->histidine) is an abnormal hemoglobin associated with increased oxygen affinity, decreased heme-heme interaction, presence of a Bohr effect, and erythrocytosis, but without obvious clinical sequelae.","Medline_3965845,Medline_7728905",-,,,keep
DESFERAL,TFRC,POLYCYTHEMIA,"Medline_1890732,Medline_9830813",TRUE,"The serum TfR was increased in iron deficiency anemia, hemolytic anemia and polycythemia and was decreased in aplastic anemia. ","Pmcoa_5226510,Medline_15993339,Medline_27384479",TRUE,"Taken together, these results demonstrated that the combination of desferal with oxaliplatin can overcome oxaliplatin resistance through the regulation of hCtr1 and TfR1, and may have beneficial effect for treatment of patient with oxaliplatin-refractory tumors.",,keep
MANNOSE 6-PHOSPHATE,TFRC,POLYCYTHEMIA,"Medline_1890732,Medline_9830813",TRUE,,"Medline_7642700,Pmcoa_2199957",FALSE,"We studied the role of endosomes acidification on the endocytic trafficking of the transferrin receptor (TfR) as a representative for the recycling pathway, the cation-dependent mannose 6-phosphate receptor (MPR) as a prototype for transport to late endosomes, and fluid-phase endocytosed HRP as a marker for transport to lysosomes.",,keep
PROCARBAZINE,ADCY1,PSORIASIS,"Medline_1244187,Medline_167799,Medline_4376892",TRUE," These results suggest that the adenyl cyclase system of the skin has different regulatory sites for adrenaline and PGE2 and that the enzyme is defective in the epidermis of the psoriatic plaque, especially at the adrenaline regulatory site.","Patent_US20150056646,Patent_US9365623,Patent_US20100303729,Patent_WO2010138727A1,Patent_US8822162",FALSE,-,"Only patent references, impossible to proove it true or false.",new
VERUCERFONT,CRHR1,PSORIASIS,"Medline_22350180,Medline_22360979,Medline_19560286",TRUE,A statistically significant increase of the expression of CRH-R1 was found in the skin biopsies of psoriasis patients compared with the control group patients.,"Medline_27109623,Pmcoa_4082482,Medline_29505471,Pmcoa_5652029",TRUE,"Animal models suggest that CRHR1 antagonists may have therapeutic utility in stress-related disorders, but these agents have not previously been investigated in patients with PTSD [22]. Functional activity and in vitro binding assays indicate that GSK561679 is a potent CRHR1 antagonist.",,keep
PEXACERFONT,CRHR1,PSORIASIS,"Medline_22350180,Medline_22360979,Medline_19560286",TRUE,,"Medline_27362504,Medline_28807676,Pmcoa_4928795,Medline_27595147,Medline_29064909,Medline_27109623,Pmcoa_3671664,Pmcoa_4462850,Pmcoa_3765344",TRUE,"On the other hand, the CRF1 antagonists, CP-316,311, showed no effect against depression in a 6-week randomized, placebo-controlled trial [18] and pexacerfont did not demonstrate efficacy compared to placebo for the treatment of generalized anxiety disorders in a multi-center clinical trial [19]. ",,keep
DELCASERTIB,DYT10,PSORIASIS,"Patent_EP0805158A3,Patent_EP0805158B1,Patent_EP0657458B1,Patent_EP1449529B1,Patent_EP0805158A2,Patent_US20050287132,Patent_EP0657458A1,Pmcoa_2678983",FALSE,"While IFN-gamma [20], IRF-1 [19,21] and CBP [22,23] were already associated with psoriasis in independent studies, there is no direct evidence in the literature regarding involvement of PKC-delta and CaMKII in the disease. On the other hand, some studies indicate that other PKC isozimes [24] and calcium signaling in general [25] may play role in the pathogenesis of psoriasis. ","Patent_EP2194124A1,Patent_EP1934338A2,Patent_US20110098224,Patent_US20070141040,Patent_WO2007035782A2,Pmcoa_4166028",-,,,keep
SORBINIL,DYT10,PSORIASIS,"Patent_EP0805158A3,Patent_EP0805158B1,Patent_EP0657458B1,Patent_EP1449529B1,Patent_EP0805158A2,Patent_US20050287132,Patent_EP0657458A1,Pmcoa_2678983",FALSE,,"Patent_US20040047919,Patent_US20060293265,Patent_US20060210651,Patent_WO2003105864A1",-,,,new
DULAGLUTIDE,GLP1R,PSORIASIS,"Medline_22160246,Medline_21744074",TRUE,"We observed an improvement in psoriasis severity in a patient within days of starting treatment with an incretin-mimetic, glucagon-like peptide-1 (GLP-1) receptor agonist. ","Medline_26009229,Medline_28283565,Patent_EP3329930A1,Medline_25029955,Medline_26656966,Medline_24742660,Medline_29483060,Medline_29377522,Pmcoa_5008205,Pmcoa_4705511,Patent_US20170275370,Pmcoa_6021307,Pmcoa_4113177,Patent_WO2017112824A2,Pmcoa_5013324,Pmcoa_4934019,Pmcoa_4509428,Medline_26059826,Medline_25860029",TRUE,"To assess the risk of acute pancreatitis during treatment with glucagon-like peptide 1 receptor agonist dulaglutide, placebo, and active comparators across phase 2/3 dulaglutide trials.",,keep
SEMAGLUTIDE,GLP1R,PSORIASIS,"Medline_22160246,Medline_21744074",TRUE,,"Medline_29574633,Medline_29439603,Pmcoa_5483425,Pmcoa_5870815",TRUE,The GLP-1R agonist semaglutide has recently been registered to treat type 2 diabetes.,,new
HQL 79,HPGDS,PSORIASIS,"Medline_23489263,Patent_US20150038499,Patent_US20150307914",FALSE,To perform GSTT1 geno- and phenotyping in psoriasis patients treated with FAE to find out whether the responder status and/or occurrence of side-effects are associated with allelic variants and enzymatic activity of GSTT1.,"Patent_US9750749,Patent_US20100075990,Patent_US20160199386,Medline_21294159,Medline_16624958,Medline_18492946,Patent_US20130079375,Patent_US9126973,Patent_US8450326,Patent_EP2350059A2,Medline_22068479,Patent_EP2350059B1,Patent_US20120015001,Patent_US9320723,Patent_WO2004016223A2,Patent_US20150099748,Patent_WO2010033977A2,Pmcoa_4486370,Pmcoa_3050850,Pmcoa_4292445,Pmcoa_3248891,Patent_US8536185,Pmcoa_5515835,Medline_16547010",-,,,keep
S-METHYLGLUTATHIONE,HPGDS,PSORIASIS,"Medline_23489263,Patent_US20150038499,Patent_US20150307914",FALSE,,"Patent_US20150038499,Medline_11305778,Patent_EP3027767A1,Patent_US20150307914,Patent_WO2015017762A1",-,,,new
PYRROLE CARBOXYLIC ACID,HPGDS,PSORIASIS,"Medline_23489263,Patent_US20150038499,Patent_US20150307914",FALSE,,"Medline_25628728,Pmcoa_4306705",-,,,new
ACETYLSEROTONIN,HPGDS,PSORIASIS,"Medline_23489263,Patent_US20150038499,Patent_US20150307914",FALSE,,"Patent_US20050089981,Patent_EP1373519B1,Patent_EP1373519A2,Patent_US7601889,Patent_WO2002077213A2",-,,,new
"1-AMINO-4-{[4-({6-CHLORO-4-[(3-SULFOPHENYL)IMINO]-1,2,3,4-TETRAHYDRO-1,3,5-TRIAZIN-2-YLIDENE}AMINO)-3-SULFOPHENYL]AMINO}-9,10-DIOXO-9,10-DIHYDROANTHRACENE-2-SULFONIC ACID",HPGDS,PSORIASIS,"Medline_23489263,Patent_US20150038499,Patent_US20150307914",FALSE,,"Medline_8100477,Medline_8481559",-,,,new
LINSITINIB,IGF1R,PSORIASIS,"Medline_10802619,Patent_EP1191941A1,Patent_US20050261230,Patent_US6900186,Patent_WO2000078341A1,Patent_EP1938819A2,Patent_EP1498121A1,Patent_US20040186169,Patent_US20090326248,Patent_US7662851,Patent_EP1597366B1,Patent_EP1597366A1,Patent_US20090286849,Patent_US20040171149,Patent_US20060234239,Patent_US20130096176,Patent_US20090111767,Patent_US8217017,Patent_US7468356,Patent_WO2004072284A1",TRUE,The findings indicate that IGF-I receptor stimulation is a rate-limiting step in psoriatic epidermal hyperplasia and that IGF-I receptor targeting by cutaneous administration of antisense oligonucleotides forms the basis of a potential new psoriasis therapy.,"Patent_US20130158264,Pmcoa_5718000,Pmcoa_4453276,Pmcoa_5302955,Pmcoa_4747355,Medline_29262576,Pmcoa_3388245,Pmcoa_4946092,Pmcoa_5732742,Pmcoa_5662764,Pmcoa_5834254,Pmcoa_5031330,Pmcoa_5226581,Pmcoa_3356071,Pmcoa_4164328,Medline_22170383,Patent_WO2016064716A1,Medline_26041671,Patent_US20110275644,Patent_US20110217309,Pmcoa_3717308,Pmcoa_3853032,Medline_26429980,Medline_26561558,Medline_29251331,Medline_28440057,Medline_24687941,Medline_25483727,Medline_25573956,Medline_24759003,Patent_EP2350317A2,Medline_27286459,Medline_29207959,Medline_24161672,Patent_US20100240665,Medline_26956669,Patent_EP2780469A1,Patent_EP3253733A1,Patent_US20120064072,Patent_US20150269307,Patent_US20160144027,Patent_US20140154264,Patent_US20170326205,Patent_US8163509,Patent_US20170258495,Patent_US9632074,Patent_US20160015709,Patent_US20170020964,Patent_US20160144028,Patent_WO2013152313A1,Patent_WO2016182988A1,Patent_WO2016125169A1,Patent_US20140303133,Patent_WO2013075059A1,Patent_WO2012167028A2,Patent_WO2010048123A2,Patent_WO2016172226A1,Pmcoa_3656383,Patent_WO2017062426A1,Pmcoa_3135278,Pmcoa_3302113,Pmcoa_3597533,Patent_US9724393,Pmcoa_5094996,Pmcoa_5065953,Pmcoa_3672007,Pmcoa_4663284,Pmcoa_4246767,Pmcoa_5381259,Pmcoa_4598970,Pmcoa_5482604,Pmcoa_5216960,Pmcoa_5464869,Pmcoa_4324539,Pmcoa_4741867,Pmcoa_4887336,Pmcoa_5048293,Pmcoa_4177604,Pmcoa_4014081,Pmcoa_4399020,Pmcoa_4835175,Pmcoa_5226784,Pmcoa_5655304,Pmcoa_5814180,Pmcoa_5482874,Patent_WO2014123476A1,Pmcoa_3868504,Pmcoa_5356237,Pmcoa_4419619,Pmcoa_3141798,Patent_EP2400985A2,Patent_US20090092596,Patent_US20120101084,Patent_US8048621,Patent_US20120189641,Patent_WO2010099139A2,Pmcoa_5111065,Patent_US20130005733",TRUE,"Nevertheless, we have shown that OSI-906 reduces both p-IGF1R steady-state protein and IGF1R signaling (i.e. p-AKT and 4E-BP-1 hyper-phosphorylation) in the MCF7 ER-positive and HCC1806 ER-negative breast cancer cell-lines, consistent with the assumption that the therapeutic inhibition of OSI-906 is mediated at least in part via IGF1R.",,keep
ROBATUMUMAB,IGF1R,PSORIASIS,"Medline_10802619,Patent_EP1191941A1,Patent_US20050261230,Patent_US6900186,Patent_WO2000078341A1,Patent_EP1938819A2,Patent_EP1498121A1,Patent_US20040186169,Patent_US20090326248,Patent_US7662851,Patent_EP1597366B1,Patent_EP1597366A1,Patent_US20090286849,Patent_US20040171149,Patent_US20060234239,Patent_US20130096176,Patent_US20090111767,Patent_US8217017,Patent_US7468356,Patent_WO2004072284A1",TRUE,,"Medline_22188815,Pmcoa_3081058,Pmcoa_4303167,Medline_24905030,Medline_20124453,Pmcoa_4149550",TRUE,"Robatumumab (also known as 19D12 and SCH 717454) is a fully human anti-IGF-1R monoclonal antibody of the immunoglobulin G1 (IgG1)/kappa isotype. It binds to the extracellular portion of human IGF-1R selectively and with high affinity, and thereby prevents IGF binding and activation of transduction events, including IGF-1R autophosphorylation, insulin receptor substrate 1 phosphorylation, and activation of downstream intracellular signaling events 19",,keep
LANTUS,IGF1R,PSORIASIS,"Medline_10802619,Patent_EP1191941A1,Patent_US20050261230,Patent_US6900186,Patent_WO2000078341A1,Patent_EP1938819A2,Patent_EP1498121A1,Patent_US20040186169,Patent_US20090326248,Patent_US7662851,Patent_EP1597366B1,Patent_EP1597366A1,Patent_US20090286849,Patent_US20040171149,Patent_US20060234239,Patent_US20130096176,Patent_US20090111767,Patent_US8217017,Patent_US7468356,Patent_WO2004072284A1",TRUE,,"Medline_20730455,Pmcoa_3355935,Pmcoa_4219851,Pmcoa_3114335,Medline_14722023,Pmcoa_3699703,Pmcoa_3712049,Pmcoa_3581051,Medline_19153208,Pmcoa_4349771,Pmcoa_2832019,Pmcoa_4531810,Pmcoa_3960261",TRUE,"In particular, in human osteosarcoma cells (Saos-2) that express IGF-1R more than IR, insulin glargine was more potent than native insulin for stimulating growth (Kurtzhals et al., 2000; Sommerfeld et al., 2010). ",,keep
CIXUTUMUMAB,IGF1R,PSORIASIS,"Medline_10802619,Patent_EP1191941A1,Patent_US20050261230,Patent_US6900186,Patent_WO2000078341A1,Patent_EP1938819A2,Patent_EP1498121A1,Patent_US20040186169,Patent_US20090326248,Patent_US7662851,Patent_EP1597366B1,Patent_EP1597366A1,Patent_US20090286849,Patent_US20040171149,Patent_US20060234239,Patent_US20130096176,Patent_US20090111767,Patent_US8217017,Patent_US7468356,Patent_WO2004072284A1",TRUE,,"Patent_US20140341922,Medline_25543125,Medline_20166202,Pmcoa_4608384,Medline_17875788,Pmcoa_3344278,Pmcoa_3113372,Pmcoa_4164328,Medline_22323052,Pmcoa_4312119,Pmcoa_3938039,Pmcoa_4059749,Patent_US20120100166,Patent_WO2013007801A1",TRUE,"IMC-A12 also mediates robust internalization and degradation of the IGF1R. Although promising single-agent activity has been observed, the most impressive effects of targeting the IGF1R with IMC-A12 have been noted when this molecule was combined with cytotoxic agents or other targeted therapeutics [140]. ",,keep
FIGITUMUMAB,IGF1R,PSORIASIS,"Medline_10802619,Patent_EP1191941A1,Patent_US20050261230,Patent_US6900186,Patent_WO2000078341A1,Patent_EP1938819A2,Patent_EP1498121A1,Patent_US20040186169,Patent_US20090326248,Patent_US7662851,Patent_EP1597366B1,Patent_EP1597366A1,Patent_US20090286849,Patent_US20040171149,Patent_US20060234239,Patent_US20130096176,Patent_US20090111767,Patent_US8217017,Patent_US7468356,Patent_WO2004072284A1",TRUE,,"Pmcoa_2920021,Pmcoa_3306383,Medline_27488947,Pmcoa_4973270,Pmcoa_4313785,Pmcoa_3359746,Medline_26287334,Pmcoa_4545894,Patent_US20120100166,Patent_EP2850229A1,Patent_US20150072895,Patent_EP2984176A2,Patent_US20160313343,Patent_WO2013173627A1,Patent_US9840728,Patent_WO2015103645A2,Patent_WO2016004233A2,Patent_US20150376678,Pmcoa_4599304",TRUE,"Administration of docetaxel and figitumumab in combination resulted in decreased sIGF-IR levels. At doses ⩾3 mg kg–1, there was a complete downregulation of sIGF-IR levels for the entire dosing cycle (Figure 2).",,keep
DUSIGITUMAB,IGF1R,PSORIASIS,"Medline_10802619,Patent_EP1191941A1,Patent_US20050261230,Patent_US6900186,Patent_WO2000078341A1,Patent_EP1938819A2,Patent_EP1498121A1,Patent_US20040186169,Patent_US20090326248,Patent_US7662851,Patent_EP1597366B1,Patent_EP1597366A1,Patent_US20090286849,Patent_US20040171149,Patent_US20060234239,Patent_US20130096176,Patent_US20090111767,Patent_US8217017,Patent_US7468356,Patent_WO2004072284A1",TRUE,,"Medline_21245093,Pmcoa_3845553,Patent_EP3082859A1,Patent_US20160324962,Patent_WO2015095329A1",TRUE,"Pharmacodynamic analysis demonstrated inhibition of IGF-1R phosphorylation in tumors in mice dosed with MEDI-573, indicating that the antitumor activity is mediated via inhibition of IGF-1R signaling pathways.",,keep
H 89 DIHYDROCHLORIDE,MSX2,PSORIASIS,"Pmcoa_5715373,Patent_WO2015067503A1",FALSE,"The neuropeptide α-MSH is a well known mediator of skin pigmentation and has recently been shown to exert anti-inflammatory and immunomodulatory activities (106). Treatment with α-MSH ameliorated psoriasis-like skin inflammation, in part by suppressing the proliferation and effector function of Th17 cells.","Patent_US5622860,Patent_US6117975",-,,,new
"PHENYL, 4-HYDROXY-",NR4A1,PSORIASIS,"Medline_26932821,Pmcoa_4774191,Pmcoa_4829133",TRUE,"Nur77 expression is elevated in synovial tissue, cartilage and prostaglandin E2 (PGE2) stimulated chondrocytes from patients with rheumatoid arthritis, psoriatic arthritis or osteoarthritis, making Nur77 an attractive target in rheumatic diseases [60–63].","Pmcoa_4452731,Patent_US20160303081",TRUE,"We have recently demonstrated that selected 1,1-bis(3'-indolyl)-1-(p-substituted phenyl)methane (C-DIM) compounds including the p-hydroxyphenyl (DIM-C-pPhOH) and p-carboxymethyl (DIM-C-pPhCO2Me) analogs bind NR4A1 and act as antagonists.",,new
"D-ORNITHINE, 2-(DIFLUOROMETHYL)-",ODC1,PSORIASIS,"Medline_8374143,Medline_7068977,Medline_7104206,Patent_EP0372941A2",TRUE,"The data obtained suggest that determination of the ornithine decarboxylase activity in epidermis might be considered as the enzyme test for measuring of any hyperproliferative process in the skin, including psoriasis.","Medline_6175860,Medline_1699428,Medline_3109383,Medline_2475032,Medline_7810648,Medline_3101528,Patent_US4914086,Medline_1482141,Medline_1671624,Medline_12467913,Medline_2971724,Medline_10903418,Medline_29635516,Medline_6432848,Medline_6692368,Patent_EP0669978A1,Patent_EP0811160A1,Patent_EP0890362A1,Patent_EP0988377B1,Patent_EP1002081B1,Patent_EP1007706A1,Patent_EP1073738A2,Patent_EP1470252B1,Patent_EP1629011A2,Patent_EP1846039A2,Patent_EP1855711B1,Medline_2498115,Medline_3009500,Medline_8167149,Medline_8618048,Patent_EP0892809B1,Patent_EP0956354B1,Patent_EP1019082B2,Patent_EP1078060A2,Patent_EP1131450B1,Patent_EP1290142A1,Patent_EP1317485A2,Patent_EP1456241A2,Patent_EP1585820A2,Patent_EP1905457B1,Patent_EP2126097A2,Patent_EP2141239A1,Patent_EP2205625B1,Patent_EP2215247A1,Patent_EP2252627B1,Patent_EP2264152B1,Patent_EP2326707B1,Patent_EP1871882A1,Patent_EP1942189A2,Patent_EP2046964A2,Patent_EP2097529A1,Patent_EP2298925A2,Patent_EP2931950A1,Patent_US20020169119,Patent_US20030175884,Patent_US20030216318,Patent_US20040014174,Patent_US20040121362,Patent_US20050158287,Patent_US20050220789,Patent_US20060235201,Patent_US20070122408,Patent_US20080184388,Patent_US20080254030,Patent_US20080255339,Patent_US20090022738,Patent_US20090186019,Patent_US20100021467,Patent_US20100317097,Patent_US20110002941,Patent_EP0927043B1,Patent_EP0969865B1,Patent_EP1210102B1,Patent_EP1232182B1,Patent_EP1490099A2,Patent_EP1587921B1,Patent_EP1590372A2,Patent_EP1673398B1,Patent_EP1716178A1,Patent_EP1720903A1,Patent_EP1857546A1,Patent_EP2360259A2,Patent_EP2380910A1,Patent_EP2395023A2,Patent_EP2438079A2,Patent_EP2552964A1,Patent_EP2809147A1,Patent_EP2938740A1,Patent_EP3250695A1,Patent_US20010013134,Patent_US20020068302,Patent_US20020086382,Patent_US20020086392,Patent_US20020106779,Patent_US20020142358,Patent_US20020146759,Patent_US20020157120,Patent_US20030086919,Patent_US20030157519,Patent_US20030180300,Patent_US20050074797,Patent_US20050132442,Patent_US20050176028,Patent_US20050221340,Patent_US20110160126,Patent_US20110294984,Patent_US20130023474,Patent_US20140127241,Patent_US20150344584,Patent_US20160168217,Patent_US20160168218,Patent_US20160251676,Patent_US20170096676,Patent_US5401650,Patent_US5643748,Patent_US5824867,Patent_US5837258,Patent_US5846712,Patent_US5932474,Patent_US6005080,Patent_US6020193,Patent_EP2155783A2,Patent_EP2162537B1,Patent_EP2180007A2,Patent_EP2208785A1,Patent_EP2340709A1,Patent_EP2356153B1,Patent_EP2387610A2,Patent_EP2463370B1,Patent_EP2809682A1,Patent_EP2814944A1,Patent_EP2964675A1,Patent_EP2964753A1,Patent_EP3041344A1,Patent_EP3051940A1,Patent_US20020098547,Patent_US20030013149,Patent_US20030036509,Patent_US20030120051,Patent_US20040014702,Patent_US20040072290,Patent_US20040115814,Patent_US20040171823,Patent_US20060035373,Patent_US20060183137,Patent_US20050221445,Patent_US20050233428,Patent_US20050272128,Patent_US20060084610,Patent_US20060147372,Patent_US20060292143,Patent_US20080301833,Patent_US20090126260,Patent_US20090253635,Patent_US20090280545,Patent_US20090325208,Patent_US20100113811,Patent_US20100285480,Patent_US20110008883,Patent_US20110256137,Patent_US20140068813,Patent_US20150079091,Patent_US20150174196,Patent_US20160076009,Patent_US20160106858,Patent_US20160168221,Patent_US20160319291,Patent_US20170283865,Patent_US6046925,Patent_US6051397,Patent_US6103877,Patent_US6323023,Patent_US6774217,Patent_US6825035,Patent_US6891082,Patent_US6908984,Patent_US6955898,Patent_US7217525,Patent_US7235710,Patent_US7348178,Patent_US7544776,Patent_US7759091,Patent_US7915398,Patent_US8062996,Patent_US8124091,Patent_US8323964,Patent_US8586712,Patent_US20070054277,Patent_US20080242611,Patent_US20090017522,Patent_US20100190161,Patent_US20100333231,Patent_US20110262439,Patent_US20110293609,Patent_US20110293619,Patent_US20120220021,Patent_US20140173774,Patent_US20140227253,Patent_US20140234904,Patent_US20160000842,Patent_US20160244770,Patent_US20160264671,Patent_US20170022517,Patent_US20170182122,Patent_US20170342430,Patent_US5491075,Medline_17183546,Medline_24197009,Medline_11435720,Medline_1995879,Medline_15175104,Patent_US5807981,Patent_US5814457,Patent_US6039950,Patent_US6326484,Patent_US6518400,Patent_US6872699,Patent_US6911528,Patent_US6927320,Patent_US6967096,Patent_US7439335,Medline_2104632,Medline_3118799,Medline_3134121,Patent_US9765404,Patent_WO1998007886A1,Patent_WO1999021009A1,Patent_WO1999023253A1,Patent_WO1999045128A2,Patent_WO2000001833A1,Patent_WO2000036124A2,Patent_WO2001031041A2,Patent_WO2001078770A1,Patent_WO2002014557A1,Patent_WO2002033115A2,Patent_WO2004029284A2,Patent_WO2004106531A1,Patent_WO2007025181A2,Patent_WO2008006028A2,Patent_WO2008150463A2,Patent_WO2009064777A2,Patent_WO2011034968A1,Patent_WO2012007557A1,Patent_WO2014138306A1,Patent_WO2014207556A1,Medline_10225001,Patent_US5804446,Patent_US6132728,Patent_US6140466,Patent_US6214794,Patent_US6232117,Patent_US6294367,Patent_US6464983,Patent_US6506578,Patent_US6656734,Patent_US6780975,Patent_US7037677,Patent_US7037678,Patent_US7060869,Patent_US7101977,Patent_US7153657,Patent_US7364845,Patent_US7465581,Patent_US7966338,Patent_US7993879,Patent_US8071789,Patent_US8163546,Patent_US8216580,Patent_US8258257,Patent_US8268553,Patent_US8292975,Patent_US8822411,Medline_10519408,Medline_10630381,Medline_1415709,Medline_2515533,Medline_2825697,Medline_3114026,Patent_US7517652,Patent_US7566768,Patent_US7732195,Patent_US8043831,Patent_US8067667,Patent_US8075641,Patent_US8283170,Patent_US9249421,Patent_US9382549,Patent_US9676833,Patent_WO1995019431A1,Patent_WO1999054440A1,Patent_WO1999066055A2,Patent_WO2000020434A1,Patent_WO2000024254A1,Patent_WO2000056905A2,Patent_WO2001007059A1,Patent_WO2001012210A1,Patent_WO2001070763A1,Patent_WO2004069876A2,Patent_WO2007106603A2,Patent_WO2008089152A2,Patent_WO2008119565A2,Medline_7559809,Medline_7639687,Medline_6803079,Medline_8017096,Medline_8094315,Medline_2862252,Medline_7958401,Medline_6809478,Patent_US9089525,Patent_US9492563,Patent_US9586996,Patent_WO1998030715A1,Patent_WO1999041281A1,Patent_WO1999058678A2,Patent_WO2001027294A1,Patent_WO2001042296A2,Patent_WO2002010214A2,Patent_WO2003025120A2,Patent_WO2004009794A2,Patent_WO2005059121A2,Patent_WO2005073249A1,Patent_WO2011034823A1,Patent_WO2013113615A1,Patent_WO2014172584A1,Patent_WO2016109840A2,Medline_3125182,Medline_23123718,Medline_3011686,Medline_8347171,Patent_EP0647275B2,Patent_EP0659217B1,Patent_EP0670896B2,Patent_EP0886644B1,Patent_EP0877547A1,Patent_EP0966478A1,Patent_EP0970199B1,Patent_EP1100535B1,Patent_EP1139750A1,Patent_EP1210102A2,Patent_EP1378570B1,Patent_EP0647275A1,Patent_EP0670896A1,Patent_EP0671923B1,Patent_EP0672128A1,Patent_WO2008120194A2,Patent_WO2014164554A1,Pmcoa_2119593,Pmcoa_5644631,Medline_8601724,Medline_9225449,Patent_EP0520843A3,Patent_EP0730606B1,Patent_EP0927043A1,Patent_EP0969865A1,Patent_EP1020528A3,Patent_EP1165586A1,Patent_EP1285966A1,Medline_3125429,Patent_EP0248217A2,Patent_EP0307247A2,Patent_EP0669978B1,Patent_EP0988377A1,Patent_EP0996726B1,Patent_EP1007706B1,Patent_EP1066390A2,Patent_EP1098664B1,Patent_EP1238073A2,Patent_EP1266014A2,Patent_EP1311680A2,Patent_EP1414861A2,Patent_EP1576101A2,Patent_EP1731164A1,Patent_EP1928897A2,Patent_EP2352765B1,Patent_EP0877547B1,Patent_EP0970199A1,Patent_EP1003531B1,Patent_EP1009805B1,Patent_EP1100535A1,Patent_EP1107768B1,Patent_EP1250155B1,Patent_EP1378570A1,Medline_6815870,Medline_8726018,Patent_EP0307247B1,Patent_EP0815116A1,Patent_EP0892849B1,Patent_EP1032837B1,Patent_EP1066390B1,Patent_EP1071700A1,Patent_EP1071752A1,Patent_EP1123398B1,Patent_WO2016134311A1,Medline_6950518,Medline_7688751,Medline_9347337,Patent_EP0215319B1,Patent_EP0307248A2,Patent_EP1058734A2,Patent_EP1088067A1,Patent_EP1137786B1,Patent_EP1285065A2,Patent_EP1629013A1,Patent_EP1637607B1,Patent_EP1685239A2,Patent_EP1819732A2,Patent_EP1924699A2,Patent_EP2046806A2,Patent_EP2057192A2,Patent_EP2171085A2,Patent_EP2188376A2,Patent_EP2203542A1,Patent_EP2292664B1,Patent_EP2431471A1,Patent_EP2726511A2,Patent_EP3240889A2,Patent_US20020132229,Patent_US20020168428,Patent_US20020192790,Patent_US20020197232,Patent_US20030147862,Patent_EP1587921A2,Patent_EP1652856A1,Patent_EP1871805A2,Patent_EP2155783B1,Patent_EP2162537A2,Patent_EP2180007B1,Patent_EP2356153A2,Patent_EP2366783B1,Patent_EP2681244B1,Patent_EP2920212A1,Patent_EP2925775A2,Patent_EP3136842A1,Patent_EP3189144A1,Patent_EP3241897A1,Patent_US20010003585,Patent_US20020169131,Patent_US20030022305,Patent_US20030074686,Patent_US20040092450,Patent_US20040241817,Patent_US20050191702,Patent_US20050244970,Patent_EP0724632B1,Patent_EP0770129B1,Patent_EP1015473A1,Patent_EP1053315A1,Patent_EP1140969B1,Patent_EP1218399A1,Patent_EP1285065B1,Patent_EP1346731A1,Patent_EP1350848A2,Patent_EP1427834A1,Patent_EP1637607A2,Patent_EP1685239B1,Patent_EP1696721A2,Patent_EP1795203A2,Patent_EP2057192B1,Patent_EP2140009A2,Patent_EP2292664A2,Patent_EP2808338A1,Patent_EP2964241A1,Patent_EP3212774A1,Patent_EP3262064A1,Patent_US20020022023,Patent_US20020155121,Patent_EP1496364A2,Patent_EP1534840A2,Patent_EP1673398A1,Patent_EP1692182B1,Patent_EP1716178B1,Patent_EP1881849A2,Patent_EP2077282B1,Patent_EP2180007B2,Patent_EP2264151A2,Patent_EP2295465B1,Patent_EP2322635A2,Patent_EP2336186A1,Patent_EP2342344A1,Patent_EP2463370A1,Patent_EP2520590A2,Patent_EP3146055A2,Patent_EP3207147A1,Patent_EP3209681A1,Patent_EP3219200A1,Patent_US20010000488,Patent_US20020157122,Patent_US20030083373,Patent_US20030103992,Patent_US20040003427,Medline_8742517,Patent_EP2935592A1,Patent_EP3143143A1,Patent_US20020025307,Patent_US20020072101,Patent_US20020090374,Patent_US20020157126,Patent_US20020165364,Patent_US20050176065,Patent_US20050244854,Patent_US20060053507,Patent_US20070025957,Patent_US20080206871,Patent_US20080299104,Patent_US20090186029,Patent_US20090196872,Patent_US20090233860,Patent_US20100041092,Patent_US20100122367,Patent_US20100151519,Patent_US20100158907,Patent_US20100169989,Patent_US20100183615,Patent_US20110239317,Patent_US20120011614,Patent_EP1554386A2,Patent_EP1896578A1,Patent_EP2020447A1,Patent_EP2077282A2,Patent_EP2205697A1,Patent_EP2264151B1,Patent_EP2295465A2,Patent_EP2322634A2,Patent_EP2322635B1,Patent_EP2366783A1,Patent_EP2809144A1,Patent_US20020037574,Patent_US20020081650,Patent_US20020168370,Patent_US20030059767,Patent_US20030143521,Patent_US20040014128,Patent_US20050037469,Patent_US20050084885,Patent_US20050107321,Patent_US20050118677,Patent_US20050164345,Patent_US20050235367,Medline_8849262,Patent_EP0892849A1,Patent_EP1002081A2,Patent_EP1071700B1,Patent_EP1071752B1,Patent_EP1073738B1,Patent_EP1141247A2,Patent_EP1375665A1,Patent_EP1470252A2,Patent_EP1530633B8,Patent_EP1572906A2,Patent_EP1311680B1,Patent_EP1313867A2,Patent_EP1348715A2,Patent_EP1383372A2,Patent_EP1414471A2,Patent_EP1414861B1,Patent_EP1573034A2,Patent_EP1732581A2,Patent_EP2180044A1,Patent_EP2352765A2,Patent_EP2473532B1,Patent_EP3216458A1,Patent_US20020142391,Patent_US20020142467,Patent_US20020169283,Patent_US20030096249,Patent_US20030165974,Patent_US20030232419,Patent_US20040223953,Patent_EP1019082A1,Patent_EP1078060B1,Patent_EP1082415A1,Patent_EP1131450A2,Patent_EP1317485B1,Patent_EP1456241B1,Patent_EP1508574A2,Patent_EP1585820B1,Patent_EP1984399A2,Patent_EP2126097B1,Patent_EP2195426A2,Patent_EP2205625A2,Patent_EP2264152A2,Patent_EP2322199B1,Patent_EP2326707A2,Patent_EP2380911A1,Patent_EP2405009B1,Patent_EP2531600A1,Patent_EP2573104A1,Medline_8428357,Patent_EP0647275B1,Patent_EP0670896B1,Patent_EP0671923A1,Patent_EP0672128B1,Patent_EP0724632A1,Patent_EP0770129A1,Patent_EP0927043B8,Patent_EP1080191A1,Patent_EP0520843B1,Patent_EP0792168A1,Patent_EP0892809A1,Patent_EP0956354A1,Patent_EP0990042A1,Patent_EP1073770A2,Patent_EP1140964B1,Patent_EP1247103A2,Patent_EP1425036A2,Patent_EP1905457A1,Patent_EP1925672A1,Patent_EP1931712A2,Patent_EP2141239B1,Patent_EP2155788A2,Patent_EP2210947B1,Patent_EP2215247B1,Patent_EP2252627A1,Patent_EP2336336A2,Patent_EP2336337B1,Patent_EP2352763B1,Patent_EP2380910B1,Patent_EP2477478B1,Patent_EP2504357B1,Patent_EP3020727A1,Patent_US20020019005,Patent_EP0215319A2,Patent_EP0307248B1,Patent_EP0520843A2,Patent_EP0554385B1,Patent_EP1019082B1,Patent_EP1020528A2,Patent_EP1073770B1,Patent_EP1082415B1,Patent_EP1117675A1,Patent_EP1247103B1,Patent_EP1355922A2,Patent_EP1524275A2,Patent_EP1888649A2,Patent_EP2210947A2,Patent_EP2322199A1,Patent_EP2333075A1,Patent_EP2336336B1,Patent_US20030176349,Patent_US20030215421,Patent_US20060039918,Patent_US20060153851,Patent_US20070071745,Patent_US20070178499,Patent_US20070259373,Patent_US20080112937,Patent_US20080182269,Patent_US20080182311,Patent_US20080184389,Patent_US20080241167,Patent_US20090081124,Patent_US20090325155,Patent_US20100136061,Patent_US20100150918,Patent_US20110081718,Patent_US20120252054,Patent_US20130212737,Patent_US20150059023,Patent_US20160015750,Patent_US20160168216,Patent_US20060142547,Patent_US20060188924,Patent_US20060240423,Patent_US20080207449,Patent_US20080244765,Patent_US20090136950,Patent_US20090214532,Patent_US20090304690,Patent_US20100022624,Patent_US20100137568,Patent_US20100151555,Patent_US20110044976,Patent_US20110124564,Patent_US20110126303,Patent_US20110159595,Patent_US20120101045,Patent_US20120122203,Patent_US20130065312,Patent_US20140194352,Patent_US20150010978,Patent_US20150259695,Patent_US20160168220,Patent_US20160229923,Patent_US20030017979,Patent_US20030054527,Patent_US20030059427,Patent_US20030077735,Patent_US20030087238,Patent_US20030213006,Patent_US20040018603,Patent_US20040038339,Patent_US20040146858,Patent_US20050246796,Patent_US20060263368,Patent_US20070178105,Patent_US20080057539,Patent_US20080131940,Patent_US20080221021,Patent_US20090087890,Patent_US20090311280,Patent_US20100275333,Patent_US20110030084,Patent_US20120107853,Patent_US20040073969,Patent_US20040248783,Patent_US20050170334,Patent_US20050271659,Patent_US20070081993,Patent_US20070111281,Patent_US20090232817,Patent_US20090253169,Patent_US20090269341,Patent_US20100112689,Patent_US20120231546,Patent_US20130084284,Patent_US20140242658,Patent_US20150047070,Patent_US20150056301,Patent_US20150307889,Patent_US20160024175,Patent_US20160068851,Patent_US20160166642,Patent_EP0659217A1,Patent_EP0886644A1,Patent_EP0909315A2,Patent_EP1301532B1,Patent_EP1385950A2,Patent_EP1772519A1,Patent_EP2220125A2,Patent_EP2370467A2,Patent_EP2407534A1,Patent_EP2444422B1,Patent_EP2646559A2,Patent_EP2971053A2,Patent_US20030022313,Patent_US20030153739,Patent_US20120309939,Patent_US20130006004,Patent_US20130028928,Patent_US20140208455,Patent_US20140364454,Patent_US20150010567,Patent_US20160076010,Patent_US20160186196,Patent_US20160194649,Patent_US20160304614,Patent_US5580757,Patent_US5654186,Patent_US5998204,Patent_US20060183686,Patent_US20070087990,Patent_US20080020406,Patent_US20080213256,Patent_US20080233571,Patent_US20090010921,Patent_US20090028832,Patent_US20090093413,Patent_US20090136983,Patent_US20090148904,Patent_US20100055701,Patent_US20100061997,Patent_US20100154070,Patent_US20100233080,Patent_US20110104263,Patent_US20110275787,Patent_US20120034228,Patent_US20120244162,Patent_US20140289895,Patent_US20160015749,Patent_US20160208009,Patent_US20160272719,Patent_EP1833848A2,Patent_EP1855711A2,Patent_EP1942189B1,Patent_EP2086575A2,Patent_EP2194131A2,Patent_EP2294179A2,Patent_EP2298925B1,Patent_EP2381761A1,Patent_EP2395024A2,Patent_EP2402374A1,Patent_EP2964764A1,Patent_US20030138782,Patent_US20030180799,Patent_US20030215850,Patent_US20040030114,Patent_US20040132657,Patent_US20040265316,Patent_US20050131217,Patent_US20060134628,Patent_US20060198820,Patent_US20060211114,Patent_US20060280749,Patent_US20070150970,Patent_US20070213269,Patent_US20050079154,Patent_US20050118628,Patent_US20060051815,Patent_US20060063230,Patent_US20060094088,Patent_US20070154989,Patent_US20080307546,Patent_US20090017022,Patent_US20090093407,Patent_US20090111126,Patent_US20090191146,Patent_US20100015148,Patent_US20100145024,Patent_US20140173780,Patent_US20150099648,Patent_US20150291677,Patent_US20160176934,Patent_US20170246278,Patent_US20170335290,Patent_EP3106468A1,Patent_EP3172240A1,Patent_US20020102267,Patent_US20020131959,Patent_US20020164719,Patent_US20030036178,Patent_US20030087377,Patent_US20040038232,Patent_US20040115815,Patent_US20040142855,Patent_US20050123546,Patent_US20050191648,Patent_US20060040853,Patent_US20090317358,Patent_US20110002910,Patent_US20120216320,Patent_US20120288918,Patent_EP1346731B1,Patent_EP1385950B1,Patent_EP1427834B1,Patent_EP2221379A1,Patent_EP2290105A1,Patent_EP2370467B1,Patent_EP2404937A1,Patent_EP2444422A2,Patent_EP2765198A2,Patent_EP2808338B1,Patent_EP2809143A1,Patent_EP2934094A1,Patent_EP2986636A1,Patent_EP3155005A2,Patent_US20030027164,Patent_US20030040476,Patent_US20030078224,Patent_US20040077581,Patent_US20040101840,Patent_US20040110289,Patent_US20050079525,Patent_US20050287530,Patent_US20030091551,Patent_US20030232776,Patent_US20040005663,Patent_US20040019926,Patent_US20050053997,Patent_US20050054090,Patent_US20060073128,Patent_US20060075523,Patent_US20060090212,Patent_US20060154283,Patent_US20060193852,Patent_US20070071742,Patent_US20080020418,Patent_US20090093026,Patent_US20090093412,Patent_US20090123940,Patent_US20090142793,Patent_US20090162366,Patent_US20100056457,Patent_US20100152051,Patent_US20100190838,Patent_EP2336337A2,Patent_EP2352763A2,Patent_EP2504357A2,Patent_EP2567969A1,Patent_EP2968601A1,Patent_EP3227477A1,Patent_US20020052015,Patent_US20020151030,Patent_US20020155431,Patent_US20030092120,Patent_US20040186067,Patent_US20050026158,Patent_US20050081268,Patent_US20050132441,Patent_US20050244841,Patent_US20050276811,Patent_US20060073564,Patent_US20060257921,Patent_US20070169227,Patent_US20090269816,Patent_US20090274816,Patent_US20100104559,Patent_US20110250611,Patent_US20160168219,Patent_US20160304897,Patent_US5597898,Patent_US5677144,Patent_US5773248,Patent_US5981708,Patent_US5985598,Patent_US6054121,Patent_US6077707,Patent_US6210664,Patent_US6242212,Patent_US6387663,Patent_US6699687,Patent_US6989146,Patent_US6995135,Patent_US6124131,Patent_US6277566,Patent_US6294653,Patent_US6303768,Patent_US6326469,Patent_US6436673,Patent_US6596493,Patent_US6645490,Patent_US6906181,Patent_US7091331,Patent_US7115390,Patent_US7157418,Patent_US7189829,Patent_US7265267,Patent_US7393682,Patent_US8685679,Patent_US8883980,Patent_US8969066,Patent_US9018451,Patent_US9371570,Patent_US20120117689,Patent_US20120122206,Patent_US20130157961,Patent_US20130288297,Patent_US20140050838,Patent_US20140308269,Patent_US20160152707,Patent_US20160251723,Patent_US20170157199,Patent_US5563246,Patent_US5874562,Patent_US6258584,Patent_US6399331,Patent_US6562613,Patent_US6565845,Patent_US20170073695,Patent_US20170121370,Patent_US5650299,Patent_US5846800,Patent_US6054271,Patent_US6281332,Patent_US6355479,Patent_US6403374,Patent_US6428998,Patent_US7018617,Patent_US7060793,Patent_US7138503,Patent_US7402430,Patent_US7863418,Patent_US7919089,Patent_US8097436,Patent_US20040241650,Patent_US20050059144,Patent_US20050059154,Patent_US20060009412,Patent_US20060078537,Patent_US20070078085,Patent_US20080280322,Patent_US20090010917,Patent_US20090093425,Patent_US20090098049,Patent_US20090123977,Patent_US20090176966,Patent_US20090233861,Patent_US20100050301,Patent_US20110151515,Patent_US20120055081,Patent_US20120064629,Patent_US20120252097,Patent_US20130219552,Patent_US20130243768,Patent_US6140066,Patent_US6368848,Patent_US6469154,Patent_US6565848,Patent_US7205272,Patent_US7220838,Patent_US7592507,Patent_US8039690,Patent_US8318436,Patent_US8318899,Patent_US8580943,Patent_US8932576,Patent_US9068008,Patent_US9493844,Patent_US9617524,Patent_US9670260,Patent_US9751924,Patent_WO1995025164A1,Patent_WO1996014877A1,Patent_WO1999047640A1,Patent_WO2000022144A2,Patent_US5346815,Patent_US5922590,Patent_US6057091,Patent_US6174526,Patent_US6326151,Patent_US6355237,Patent_US6555674,Patent_US6664039,Patent_US6685938,Patent_US6710227,Patent_US6815418,Patent_US6838079,Patent_US6908612,Patent_US7148006,Patent_US20080095770,Patent_US20080286277,Patent_US20090092578,Patent_US20090148848,Patent_US20090186806,Patent_US20090246766,Patent_US20100086532,Patent_US20100129394,Patent_US20100287671,Patent_US20100304384,Patent_US20110034372,Patent_US20110166337,Patent_US20110171230,Patent_US20120094908,Patent_US20120144530,Patent_US20130197088,Patent_US20130236943,Patent_US20140047581,Patent_US20140073005,Patent_US20170009250,Patent_US5750366,Patent_US5928884,Patent_US6030785,Patent_US6054321,Patent_US6608239,Patent_US6790941,Patent_US6821957,Patent_US7314914,Patent_US7364730,Patent_US7399473,Patent_US7524972,Patent_US8114853,Patent_US8669059,Patent_US8785722,Patent_US9206260,Patent_US9255134,Patent_US9297019,Patent_US20130183331,Patent_US20130217577,Patent_US20130224205,Patent_US20130338038,Patent_US20140041080,Patent_US20140302583,Patent_US20150143588,Patent_US20150284442,Patent_US20160200788,Patent_US20160298174,Patent_US20170182123,Patent_US20170232067,Patent_US5712097,Patent_US5981703,Patent_US5985583,Patent_US20060222657,Patent_US20070041942,Patent_US20070185074,Patent_US20100210525,Patent_US20110104148,Patent_US20110111461,Patent_US20120251529,Patent_US20120309014,Patent_US20130007911,Patent_US20130129730,Patent_US20140302577,Patent_US20150064708,Patent_US20160168215,Patent_US20160287663,Patent_US20170191042,Patent_US20170327551,Patent_US5705625,Patent_US20110275107,Patent_US20120058535,Patent_US20120116138,Patent_US20120142763,Patent_US20120322102,Patent_US20130018000,Patent_US20140243266,Patent_US20140298547,Patent_US20160017048,Patent_US20160075755,Patent_US20170015745,Patent_US5686240,Patent_US5856111,Patent_US5959174,Patent_US6008378,Patent_US20110256544,Patent_US20130338017,Patent_US20140205625,Patent_US20150051081,Patent_US20160045565,Patent_US20160168222,Patent_US5356804,Patent_US5559022,Patent_US5756668,Patent_US5853716,Patent_US5854392,Patent_US5869610,Patent_US7045305,Patent_US7175995,Patent_US7476657,Patent_US7829333,Patent_US7947495,Patent_US8076459,Patent_US8133709,Patent_US8198042,Patent_US8784821,Patent_US8933296,Patent_US9145528,Patent_WO1996000586A2,Patent_WO1998056936A1,Patent_WO1999054463A2,Patent_WO1999057312A1,Patent_WO1999061590A1,Patent_WO2000034226A1,Patent_WO2000077196A1,Patent_WO2001034647A2,Patent_WO2002012286A2,Patent_WO2002016655A2,Patent_WO2002047466A2,Patent_WO2002081490A2,Patent_WO2003017937A2,Patent_WO1994000590A1,Patent_WO1994005811A1,Patent_WO1998030576A1,Patent_WO2000036091A2,Patent_WO2000037488A2,Patent_WO2003016480A2,Patent_WO2006029078A2,Patent_WO2006066960A1,Patent_WO2007095152A2,Patent_WO2008070367A2,Patent_WO2009124282A1,Patent_WO2013126512A1,Patent_WO2014145776A2,Patent_WO2016065106A1,Patent_WO2016149665A1,Patent_US7041801,Patent_US7074617,Patent_US7119251,Patent_US7309816,Patent_US7459541,Patent_US7575923,Patent_US7585841,Patent_US7659120,Patent_US7696405,Patent_US7833784,Patent_US7927850,Patent_US8273328,Patent_US8394771,Patent_US8614065,Patent_US8790645,Patent_US9068005,Patent_US9139654,Patent_US9260522,Patent_US9273107,Patent_US9309317,Patent_US9631023,Patent_US8193414,Patent_US8273867,Patent_US8367374,Patent_US8481286,Patent_US8486659,Patent_US8993256,Patent_US9410159,Patent_US9587036,Patent_WO1994008598A1,Patent_WO1996018639A1,Patent_WO1997018230A1,Patent_WO2000078921A2,Patent_WO2001032685A2,Patent_WO2001053348A2,Patent_WO2002012514A2,Patent_WO2002044210A2,Patent_WO2002099117A2,Patent_WO2003016333A2,Patent_WO2003025185A1,Patent_WO2003059948A1,Patent_WO2004075635A2,Patent_WO2004083434A1,Patent_WO2005054427A2,Patent_WO2008008476A2,Patent_WO2008112970A2,Patent_WO2008119567A2,Patent_US20140161767,Patent_US20140212408,Patent_US20140255513,Patent_US20150067913,Patent_US20150132829,Patent_US20150152423,Patent_US20160310532,Patent_US20170073690,Patent_US5773278,Patent_US5928922,Patent_US6177401,Patent_US6355480,Patent_US6723538,Patent_US6825325,Patent_US6900289,Patent_WO2000055169A1,Patent_WO2001003722A1,Patent_WO2001030374A1,Patent_WO2001053325A2,Patent_WO2001089317A2,Patent_WO2003092724A1,Patent_WO2004065577A2,Patent_WO2005040220A1,Patent_WO2009039015A2,Patent_WO2010019696A2,Patent_WO2010019813A2,Patent_WO2012074868A2,Patent_WO2014085365A2,Patent_WO2016061574A1,Patent_WO2017024233A1,Patent_WO2017148880A1,Pmcoa_1810305,Patent_US7608683,Patent_US7692065,Patent_US7906329,Patent_US7931901,Patent_US7964399,Patent_US8007778,Patent_US8334369,Patent_US8349320,Patent_US8609371,Patent_US8951966,Patent_US9074008,Patent_US9260493,Patent_WO1995009912A1,Patent_WO1995023231A1,Patent_WO1996025423A1,Patent_WO1996025666A1,Patent_WO1997037684A1,Patent_WO1997046256A1,Patent_WO1998037413A1,Patent_US20170275650,Patent_US5002879,Patent_US5382524,Patent_US5846796,Patent_US5916792,Patent_US5998136,Patent_US6127523,Patent_US6235498,Patent_US6562799,Patent_US6593135,Patent_US6670127,Patent_US6759063,Patent_US6808893,Patent_US6897029,Patent_US7112324,Patent_US7220834,Patent_US8013138,Patent_US9315771,Patent_WO1994000562A1,Patent_WO1995009656A1,Patent_WO1995013387A1,Patent_WO1997045543A2,Patent_WO2001012127A2,Patent_WO2001019845A1,Patent_WO2001046698A2,Patent_WO2003015763A1,Patent_WO2003078600A2,Patent_WO2003080644A2,Patent_WO2003091413A2,Patent_WO2004106383A1,Patent_WO2008051612A2,Patent_WO2008054595A2,Patent_WO2011137245A2,Patent_WO2012034865A1,Patent_WO2013052755A1,Patent_WO2014100406A1,Patent_WO2017023770A1,Patent_US6197928,Patent_US6465210,Patent_US6638736,Patent_US7741451,Patent_US8101188,Patent_US8143039,Patent_US8530621,Patent_US8999324,Patent_US9150836,Patent_US9221872,Patent_US9580483,Patent_US9765350,Patent_WO1999003974A1,Patent_WO1999006559A1,Patent_WO1999053031A2,Patent_WO1999054342A1,Patent_WO2001030968A2,Patent_WO2001071005A2,Patent_WO2001085946A2,Patent_WO2001090147A2,Patent_WO2001090344A1,Patent_WO2002053589A2,Patent_WO2002081647A2,Patent_US5767252,Patent_US5840842,Patent_US5851999,Patent_US5861266,Patent_US6005092,Patent_US6541218,Patent_US6617440,Patent_US6699677,Patent_US7560287,Patent_US8021856,Patent_US9297018,Patent_US9631198,Patent_WO1997038710A1,Patent_WO1998000440A1,Patent_WO1998031823A1,Patent_WO1998047148A1,Patent_WO1999009162A2,Patent_US6451569,Patent_US6458534,Patent_US6593110,Patent_US6677307,Patent_US6890745,Patent_US7459308,Patent_US7521536,Patent_US7696324,Patent_US7727741,Patent_US7749366,Patent_US8071733,Patent_US8183354,Patent_US8236751,Patent_US8753842,Patent_US9290557,Patent_US9631170,Patent_US9694058,Patent_WO1997018227A1,Patent_WO1998054311A1,Patent_WO1999010509A1,Patent_US6083713,Patent_US6242568,Patent_US6686458,Patent_US7087388,Patent_US7109033,Patent_US7166702,Patent_US7311920,Patent_US7507705,Patent_US7807872,Patent_US8088380,Patent_US8124830,Patent_US8530225,Patent_US8685687,Patent_US8859234,Patent_US8987433,Patent_US9102736,Patent_US9133489,Patent_US9345744,Patent_US9359614,Patent_US9695372,Patent_WO1993020197A1,Patent_WO1994012628A1,Patent_WO2003054017A2,Patent_WO2003068967A2,Patent_WO2004033619A2,Patent_WO2004042023A2,Patent_WO2008097585A2,Patent_WO2011056886A2,Patent_WO2011063320A2,Patent_WO2013116782A1,Patent_WO2013134651A1,Patent_WO2014164544A1,Patent_WO2015173398A1,Patent_WO2016054107A1,Patent_WO2017218355A1,Pmcoa_3206444,Patent_WO1998006737A1,Patent_WO1999054489A1,Patent_WO2001081614A2,Patent_WO2003035696A2,Patent_WO2003066821A2,Patent_WO2006014642A1,Patent_WO2009019208A1,Patent_WO2009042538A2,Patent_WO2013116700A1,Patent_WO2014138704A1,Patent_WO2016172372A1,Patent_WO2009064815A1,Patent_WO2010081842A2,Patent_WO2011097261A1,Patent_WO2013163423A1,Patent_US7192736,Patent_US7371723,Patent_US7442783,Patent_US7662377,Patent_US7718177,Patent_US7790951,Patent_US7846432,Patent_US8003106,Patent_US8101722,Patent_US8263412,Patent_US8546535,Patent_US9273090,Patent_US9296820,Patent_WO1994019485A1,Patent_WO1998040477A1,Patent_WO1998052581A1,Patent_WO2000006195A1,Patent_WO2000023593A2,Patent_WO2000036919A1,Patent_WO2001045751A1,Patent_WO2001090306A2,Patent_WO2003008540A2,Patent_WO2004106380A2,Patent_WO2006074451A2,Patent_WO1998055638A1,Patent_WO2001026536A2,Patent_WO2001029068A2,Patent_WO2001090314A1,Patent_WO2002068471A2,Patent_WO2003027299A2,Patent_WO2004001060A2,Patent_WO2004065540A2,Patent_WO2005047479A2,Patent_WO2008080218A1,Patent_WO2008119566A2,Patent_WO2011034936A1,Patent_WO2013123244A1,Patent_WO2015082449A2,Patent_WO2016014621A1,Patent_WO2016135130A1,Patent_WO2017069291A1,Patent_US8293975,Patent_US8362216,Patent_US8623644,Patent_US8633139,Patent_US8642742,Patent_US9644213,Patent_US9718885,Patent_WO1996031617A1,Patent_WO1997026271A1,Patent_WO1997039133A1,Patent_WO1999031260A2,Patent_WO1999057311A2,Patent_WO1999060114A1,Patent_WO2000029592A2,Patent_WO2003033650A2,Patent_WO2005003323A2,Patent_WO2006122442A1,Patent_WO2009036087A1,Patent_WO2010042138A1,Patent_WO2015179621A2,Patent_WO2005077982A1,Patent_WO2006044486A2,Patent_WO2009045550A2,Patent_WO2009094634A1,Patent_WO2010129853A2,Patent_WO2011121110A1,Patent_WO2014105939A1,Patent_WO2015034885A1,Patent_WO2015066637A1,Patent_WO2015195509A2,Pmcoa_5481400,Pmcoa_5574924,Patent_WO1999016457A2,Patent_WO2000036083A2,Patent_WO2001077351A1,Patent_WO2002083901A2,Patent_WO2004065596A2,Patent_WO2006012222A2,Patent_WO2008150461A2,Patent_WO2009039201A1,Patent_WO2009158658A2,Patent_WO2010141471A2,Patent_WO2014089513A1,Patent_WO2016073855A1,Patent_WO2016089829A1,Pmcoa_3940083,Pmcoa_436064,Patent_WO1999021013A1,Patent_WO1999051986A1,Patent_WO1999060140A2,Patent_WO2000000604A1,Patent_WO2001004266A1,Patent_WO2001022982A2,Patent_WO2001042294A2,Patent_WO2001083755A2,Patent_WO2003007889A2,Patent_WO2003059942A2,Patent_WO2004009796A2,Patent_WO2004018673A2,Patent_WO2008002600A2,Patent_WO2008109779A2,Patent_WO2009132308A2,Patent_WO2011113005A2,Patent_WO2015051083A1,Patent_WO2015167956A1,Patent_WO2017148879A1,Patent_WO2017173005A1,Patent_WO1997017988A1,Patent_WO1999017798A1,Patent_WO1999038965A1,Patent_WO2000004926A2,Patent_WO2001085908A2,Patent_WO2002006458A2,Patent_WO2003068167A2,Patent_WO2004061113A1,Patent_WO2006100582A1,Patent_WO2007011827A2,Patent_WO2010078156A1,Patent_WO2013123226A1,Patent_WO2014138314A1,Patent_WO2015183890A2,Patent_WO2009036067A2,Patent_WO2013116768A1,Patent_WO2014078533A1,Patent_WO2014093736A1,Patent_WO2014100234A1,Patent_WO2016036923A1,Patent_WO2016070119A1,Patent_WO2017083276A1,Patent_WO2017172996A1,Patent_WO2016123122A1,Medline_1551519,Medline_1997467,Medline_3112767,Medline_3139441,Patent_WO2001009358A1,Medline_8457607,Medline_11539696,Pmcoa_5872161,Medline_3917400,Medline_6407845,Pmcoa_3820612,Medline_6406047,Medline_11162600,Medline_3931086,Patent_US20020019338,Patent_EP1599587A2,Patent_US6630511,Patent_WO2005003164A2,Pmcoa_2259317,Pmcoa_5921585,Medline_1694401",TRUE,"Polyamines and ornithine decarboxylase (ODC) are essential for cell proliferation. DL-α-difluoromethylornithine (DFMO), a synthetic inhibitor of ODC, induces G1 arrest through dephosphorylation of retinoblastoma protein (pRb).",,keep
DEHSPM,ODC1,PSORIASIS,"Medline_8374143,Medline_7068977,Medline_7104206,Patent_EP0372941A2",TRUE,,"Medline_8371417,Medline_1628366,Patent_US20020045780,Patent_US6235794",TRUE,"Both analogues were strikingly more potent than DFMO. DEHSPM and DENSPM suppressed the activity of the major biosynthetic enzymes, ornithine decarboxylase and S-adenosylmethionine decarboxylase.",,keep
L(-)-ALPHA-METHYLALANINE,ODC1,PSORIASIS,"Medline_8374143,Medline_7068977,Medline_7104206,Patent_EP0372941A2",TRUE,,"Medline_7115771,Medline_3420115",FALSE,-,,new
ROXADUSTAT,PDC,PSORIASIS,"Patent_EP2286835A1,Patent_US20090155286,Pmcoa_2212894,Medline_15998792",FALSE,"We show that plasmacytoid predendritic cells (PDCs), the natural interferon (IFN)-α–producing cells, infiltrate the skin of psoriatic patients and become activated to produce IFN-α early during disease formation.","Pmcoa_5359007,Patent_WO2017027810A2,Pmcoa_5201116,Pmcoa_5374523,Pmcoa_5097156",-,,,keep
PICLAMILAST,PDE4A,PSORIASIS,"Medline_29387588,Pmcoa_5683107,Patent_US20160045475,Patent_US20110318741,Pmcoa_5854648,Patent_WO2016025686A1,Medline_21859393,Pmcoa_5698795,Medline_26806620",TRUE,"One novel oral compound that has been recently established for the treatment of PsO and PsA is apremilast, a small molecule PDE4 inhibitor. ","Patent_EP1551805A1,Medline_11834608,Medline_9559913,Patent_EP1551805B1,Patent_US20030186943,Patent_US6458829,Patent_US6770658,Patent_WO2000014083A1,Patent_US20090105281,Patent_US20090239884,Patent_EP1276897A2,Patent_US20110136803,Patent_US7671050,Medline_15765929,Medline_15962112,Pmcoa_4461257,Patent_EP1567136A1,Medline_9515552,Medline_20082309,Medline_10640302,Patent_EP1301796A2,Patent_EP1836207B1,Patent_EP1874775A2,Medline_22023548,Medline_17659276,Patent_EP1791543B1,Patent_EP1601675A1,Patent_EP1836207A2,Patent_EP1874775B1,Patent_EP1791543A2,Patent_US20100286140,Patent_US20030187056,Patent_US7851472,Patent_US20060079540,Patent_US20080280907,Patent_US20080312225,Patent_US20090005372,Patent_US8106047,Patent_US20040018504,Patent_US20060106037,Pmcoa_2881047,Patent_US7282347,Patent_WO2001079526A2,Patent_WO2004089953A1,Patent_WO2004047817A1,Pmcoa_4139869,Patent_WO2002003072A2,Pmcoa_2836961,Medline_15339393",TRUE,"The selective PDE4 inhibitors Piclamilast and Roflumilast partially attenuated IL-1beta-induced NO production whereas selective inhibitors of PDE2 (EHNA), PDE3 (Motapizone) or PDE5 (Sildenafil) were inactive.",,keep
MILRINONE,PDE4A,PSORIASIS,"Medline_29387588,Pmcoa_5683107,Patent_US20160045475,Patent_US20110318741,Pmcoa_5854648,Patent_WO2016025686A1,Medline_21859393,Pmcoa_5698795,Medline_26806620",TRUE,,"Pmcoa_3471891,Patent_EP2586441A1,Patent_US20130029989,Patent_US20130172356,Patent_US9371307,Patent_US20160000750,Patent_US20150080451,Patent_WO2013039985A2,Medline_9432022,Patent_US20030069169,Patent_EP1370211A2,Pmcoa_5837217,Patent_WO2002069905A2,Medline_12652111,Patent_US20070249668,Patent_US20120083443",TRUE,"The predominant PDE3A inhibitor (and less potent PDE4 inhibitor) milrinone (Bethke et al., 1992) led to a positive inotropic (+97%) and lusitropic (RT: −22%) response in hAT, but did not have a significant effect on hiPSC-EHTs. ",,keep
HT-0712,PDE4A,PSORIASIS,"Medline_29387588,Pmcoa_5683107,Patent_US20160045475,Patent_US20110318741,Pmcoa_5854648,Patent_WO2016025686A1,Medline_21859393,Pmcoa_5698795,Medline_26806620",TRUE,,"Medline_28772081,Patent_EP2313098A1,Medline_24964813,Patent_WO2010009453A1,Pmcoa_4523784",TRUE,"Studies with PDE4 inhibitors (HT-0712, roflumilast and BPN14770) in healthy elderly and elderly with age-associated memory impairments indicate that the optimum dose and/or inhibiting the most relevant PDE isoform hold great promise when tested in the appropriate population of patients with MCI or AD eventually.",,keep
MESOPRAM,PDE4A,PSORIASIS,"Medline_29387588,Pmcoa_5683107,Patent_US20160045475,Patent_US20110318741,Pmcoa_5854648,Patent_WO2016025686A1,Medline_21859393,Pmcoa_5698795,Medline_26806620",TRUE,,"Patent_EP2231159A1,Patent_US20080182845,Patent_US20100087436,Patent_US20090176785,Patent_US20160175316,Patent_US20160101109,Patent_WO2017213695A1,Patent_WO2009064938A1,Pmcoa_3585290,Patent_WO2008064116A2",TRUE,"The PDE4 inhibitors rolipram, mesopram and tetomilast improved DSS-colitis in a preventive, therapeutic and chronic setting [9],[10],[33],[34].",,keep
CHEMBL3113974,PDE4A,PSORIASIS,"Medline_29387588,Pmcoa_5683107,Patent_US20160045475,Patent_US20110318741,Pmcoa_5854648,Patent_WO2016025686A1,Medline_21859393,Pmcoa_5698795,Medline_26806620",TRUE,,"Medline_26945156,Medline_28768120,Clinicaltrial_NCT01689571,Medline_24865624,Pmcoa_4521666,Medline_25733029,Medline_29307855,Pmcoa_5735647,Medline_28596292,Medline_25576075",TRUE,CHF6001 is an inhaled PDE4 inhibitor with proven anti-inflammatory properties in animal models.,,new
MELARSOPROL,PML,PSORIASIS,"Pmcoa_5365096,Pmcoa_3972027",FALSE,"Such occurrences of DMF-associated PML in both patients with MS and psoriasis have been associated with severe lymphopenia, typically defined as TLC <500 cells/mm3, which occurs in only ∼5% of treated patients.","Patent_US20030211171,Patent_EP2255800B1,Patent_US20040146581,Patent_EP1964557B1,Patent_WO1999024029A1,Patent_EP1964557A1,Patent_US20040146579,Patent_US20020013371,Patent_EP1037625A1,Patent_EP2255800A1,Patent_US20030099719,Medline_9716575,Patent_US20040146570,Patent_US20040146582,Patent_US7879364,Patent_US20040146571,Patent_US20040146583,Patent_US20040146568,Patent_US20040146569,Patent_US20040146574,Patent_US6855339,Patent_US6982096,Patent_US20040146576,Patent_US20060029681,Patent_US20110091573,Patent_US20040146572,Patent_US20040151782,Patent_US20040146573,Patent_US20040146577,Patent_US6884439,Patent_US6861076",-,-,,keep
ALEGLITAZAR,PPARA,PSORIASIS,"Pmcoa_3351437,Medline_22606335,Patent_EP1646383A1,Patent_EP2793876A1,Patent_US20070099969,Patent_US20130158077,Patent_US20150133507,Patent_US20170065571,Patent_US20130172391,Patent_US7339065,Patent_US9504679,Patent_WO2005009437A1,Patent_WO2013092269A1,Pmcoa_4884357",FALSE,Our data suggest that topical inhibition of PPAR β/δ to treat psoriasis may warrant further exploration.,"Pmcoa_3816132,Pmcoa_3996310,Pmcoa_3504387",-,,,new
FOTEMUSTINE,MGMT,SARCOIDOSIS,"Pmcoa_3512464,Medline_23140380",FALSE,Further studies are required to address other basic molecular mechanisms involved in reduced MGMT expression. This study underlines the possible role of DNA methylation in oncosuppressor inactivation in equine sarcoids.,"Medline_20556481,Pmcoa_4350346",-,,,new
SODIUM THIOSULFATE,TST,SARCOIDOSIS,"Pmcoa_4298936,Pmcoa_5440415,Pmcoa_3401691",FALSE,"Anergy to TST was seen in 87 per cent of patients, consistent with previous observation in India2. The TST is frequently used to distinguish it from tuberculosis since a negative TST is highly sensitive for sarcoidosis.","Pmcoa_5646106,Patent_US20150290323,Patent_US20150297535,Patent_US9375407,Patent_US20150290143,Patent_WO2015157749A2,Patent_WO2015157750A1,Patent_US9456996,Patent_US20170071876,Patent_US20080227746,Patent_US8431561,Patent_WO2006009874A2,Patent_US20140120159",-,,,new
VOLIBRIS,EDNRA,SCLERODERMA,"Pmcoa_4566861,Patent_EP2271326A1,Patent_US20110201691,Patent_US9555013,Patent_WO2009118541A1",TRUE,"In this work, we provide evidence that macitentan (MAC), a novel specific ETAR/ETBR antagonist [21], prevents SSc FB activation induced by TGF-β, blocking protein collagen 1 alpha 1 (Col1A1) production and α-SMA expression.","Medline_12654557,Medline_12671526,Medline_15838252,Medline_11750590",TRUE,"Therefore, the effect of the novel and ET(A) receptor selective antagonist LU 208075 was characterized by the contraction and relaxation induced by ET-1 and bigET-1 on rat basilar artery.",,new
ALFADEX,GLB1,SCLERODERMA,"Medline_2128055,Medline_6785118,Medline_16285646",TRUE,"The concentration of type III collagen aminopropeptide and the activity of lysosomal beta-galactosidase were determined in the serum of patients with progressive sclerosis (PS), silicosis and PS associated with silicosis.","Medline_25670982,Pmcoa_4311648",FALSE,-,,keep
GEPIRONE,HTR1A,SCLERODERMA,"Medline_27586891,Pmcoa_5009650",TRUE,"Serotonin (5-HT) is considered a key neurotransmitter and acute studies, both in healthy subjects and patients with SSc, have shown that agonists of specific class of its receptors, such as 5-HT1A, could be a putative therapeutic option [6, 8, 9]. ","Medline_1978370,Patent_WO2002102988A2,Patent_US7132287,Patent_US20030082802,Medline_11892924,Medline_1682780,Medline_1350349,Medline_8131153,Medline_2905533,Medline_2157231,Medline_10523050,Medline_2145592,Medline_12707493,Medline_1973905,Medline_14685301,Medline_2524857,Medline_9822768,Medline_7902588,Medline_7617823,Pmcoa_4408952,Medline_2901112,Patent_US7425558,Patent_EP1881851A1,Medline_2466516,Medline_2565390,Patent_US20080070925,Patent_EP1874756A1,Patent_EP1971337A1,Patent_US20060263299,Patent_WO2006116165A1,Patent_EP1871355A1,Patent_EP1871358A1,Patent_US20060287335,Patent_WO2006116149A1,Patent_EP1871755A1,Patent_WO2005094827A1,Patent_US20060287333,Patent_WO2006116150A1,Patent_WO2006116170A1,Patent_WO2007081374A1,Patent_EP1871356A1,Patent_WO2008052078A2,Patent_WO2006116151A1,Patent_WO2006124259A1,Medline_8788529",TRUE,"Twenty-four patients with major depression were treated in a single-blind design with 25 mg to 75 mg gepirone, a pyrimidinyl piperidinedione analog of buspirone with serotonin1A (5-HT1A) receptor affinity properties.",,keep
VILAZODONE,HTR1A,SCLERODERMA,"Medline_27586891,Pmcoa_5009650",TRUE,,"Pmcoa_4880584,Pmcoa_3363296,Medline_15740724,Medline_28705022,Pmcoa_5091830,Pmcoa_5693328,Pmcoa_4922821,Pmcoa_4048143,Medline_24419272,Pmcoa_4841022",TRUE,Vilazodone is known to contain a selective serotonin (5-HT) reuptake inhibitor with 5-HT1A receptor partial agonist profile.10,,keep
LESOPITRAN,HTR1A,SCLERODERMA,"Medline_27586891,Pmcoa_5009650",TRUE,,"Medline_15331910,Medline_8026543",TRUE,The agonist effect of lesopitron on 5-HT1A receptors and its marked hypothermic effect is an added value for this drug and a stimulus to the study of its possible neuroprotective action.,,keep
ELTOPRAZINE,HTR1A,SCLERODERMA,"Medline_27586891,Pmcoa_5009650",TRUE,,"Medline_7473558,Medline_2340856",TRUE," The pharmacological and anatomical data indicate that eltoprazine binds to 5-HT1A, 5-HT1B and to a lesser extent to 5-HT1C binding sites in the rat brain. These results emphasize the important role of serotonin in the regulation of offensive aggression and suggest that eltoprazine may serve as a new tool to study the involvement of central 5-HT1 receptors in the expression of this behaviour.",,keep
ZOTEPINE,HTR1A,SCLERODERMA,"Medline_27586891,Pmcoa_5009650",TRUE,,"Medline_2894736,Medline_7871012",TRUE,Radioligand binding studies using [3H]-8-OH-DPAT demonstrated that zotepine possessed weak affinity for 5-HT1A receptor; others lacked affinity.,,new
ERGOTAMINE,HTR1A,SCLERODERMA,"Medline_27586891,Pmcoa_5009650",TRUE,,"Medline_9778659,Medline_24975101",TRUE,"In humans, ergotamine also displayed some 5-HT1A receptor activity but, probably because of lack of receptor selectivity, it did not present the same profile as other 5-HT1A receptor agonists.",,new
LORCASERIN,HTR2A,SCLERODERMA,"Medline_19435465,Pmcoa_2688170,Pmcoa_2688175",FALSE,Authors found no polymorphism association of 5HT2A and scleroderma,"Pmcoa_5787931,Pmcoa_3038640,Pmcoa_4825944",-,,,keep
SERTINDOLE,HTR2A,SCLERODERMA,"Medline_19435465,Pmcoa_2688170,Pmcoa_2688175",FALSE,,"Medline_9595889,Medline_23861640,Pmcoa_3663609,Medline_7667352",-,,,new
ESTRAMUSTINE,MAPK1,SCLERODERMA,"Medline_27650973,Pmcoa_5030663,Medline_25889655,Pmcoa_3008687,Pmcoa_5811759,Patent_US20090221481",TRUE,"In summary, our study revealed that S100A9 exacerbated skin fibrosis in a mouse model of scleroderma, and enhanced the expression of RAGE and the activation of ERK1/2 MAPK and NF-κB signaling pathways in the skin tissues.","Medline_11720482,Pmcoa_2375254",TRUE,"We demonstrated that ERK2 was activated rapidly by vinorelbine, and was inhibited by either paclitaxel or estramustine.",,keep
CARBOCISTEINE,MAPK1,SCLERODERMA,"Medline_27650973,Pmcoa_5030663,Medline_25889655,Pmcoa_3008687,Pmcoa_5811759,Patent_US20090221481",TRUE,,"Patent_US20140343149,Patent_US9216163,Medline_26997568,Medline_25533503",TRUE,"urthermore, pretreatment with carbocisteine significantly decreased TNF-α-induced phosphorylation of NF-κB p65 and ERK1/2 MAPK, and inhibited the nuclear translocation of p65 subunit in A549 cells.",,keep
OTX 008,MAPK1,SCLERODERMA,"Medline_27650973,Pmcoa_5030663,Medline_25889655,Pmcoa_3008687,Pmcoa_5811759,Patent_US20090221481",TRUE,,"Patent_US20140243415,Medline_25042151",TRUE,"In SQ20B and A2780-1A9 cells, OTX008 inhibited Gal1 expression and ERK1/2 and AKT-dependent survival pathways, and induced G2/M cell cycle arrest through CDK1.",,keep
"4-(1,2-DIHYDROXYETHYL)BENZENE-1,2-DIOL",MAPK1,SCLERODERMA,"Medline_27650973,Pmcoa_5030663,Medline_25889655,Pmcoa_3008687,Pmcoa_5811759,Patent_US20090221481",TRUE,,"Pmcoa_3742461,Pmcoa_3485740",FALSE,"DHPG can induce the phosphorylation of ERK1/2 in striatal neurons in vivo and in cultures (Mao et al., 2005, 2008). ",,keep
I-BET762,MAPK1,SCLERODERMA,"Medline_27650973,Pmcoa_5030663,Medline_25889655,Pmcoa_3008687,Pmcoa_5811759,Patent_US20090221481",TRUE,,"Pmcoa_5970200,Medline_28254412,Medline_29674704,Pmcoa_5908790",TRUE,"In contrast to RKO results, we observed minimal potency shifts for trametinib in other RAS pathway mutant cell lines sensitive to the BET/MEK combination, such as the PaCa cell line HPAF-II (Supplemental Figure S17), and co-treatment with GSK525762 did not further reduce p-ERK1/2 compared to trametinib treatment in these cells. ",,new
AMINO PYRIMIDINE,MAPK1,SCLERODERMA,"Medline_27650973,Pmcoa_5030663,Medline_25889655,Pmcoa_3008687,Pmcoa_5811759,Patent_US20090221481",TRUE,,"Patent_EP3041471A1,Patent_WO2015032840A1",FALSE,-,"Only patent references, impossible to proove it true or false.",new
JNJ 38877605,MAPK1,SCLERODERMA,"Medline_27650973,Pmcoa_5030663,Medline_25889655,Pmcoa_3008687,Pmcoa_5811759,Patent_US20090221481",TRUE,,"Pmcoa_5609899,Pmcoa_5438713",TRUE,"Accordingly, HGF or fibroblasts reactivated ERK1/2 and AKT signaling upon pharmacological MET inhibition by JNJ38877605.",,new
DIHYDROXYPHENYLALANINE,MAPK1,SCLERODERMA,"Medline_27650973,Pmcoa_5030663,Medline_25889655,Pmcoa_3008687,Pmcoa_5811759,Patent_US20090221481",TRUE,,"Medline_17662258,Medline_16139809",TRUE,L-DOPA produces pronounced activation of ERK1/2 signaling in the dopamine-denervated striatum through a D1-receptor-dependent mechanism.,,new
LM-609,SERPINF1,SCLERODERMA,"Pmcoa_5867407,Medline_29259049",TRUE,"In contrast, in early diffuse SSc, we observed a strong staining for PEDF within the lower reticular dermis, both in fibroblasts and around blood vessels","Pmcoa_4889158,Medline_27293373",TRUE,"As PEDF was shown to act as an anti-angiogenic and anti-inflammatory agent in the eye both in vitro and in vivo [54-57,72], it is surprising that the increase in PEDF by LM-609 treatment was not able to suppress the expression of pro-angiogenic and pro-inflammatory genes in the RPE-EC co-culture system, while, in contrast, SAS treatment significantly suppressed the expression of these genes (Figure 4).",,keep
MESOL,SIGLEC1,SCLERODERMA,"Pmcoa_5331713,Medline_17328080",TRUE,"Increased expression of Siglec-1 in circulating SSc monocytes and tissue macrophages suggests that type I IFN-mediated activation of monocytes occurs in SSc, possibly through TLR activation of IFN secretion.","Patent_US9816197,Patent_US20140332393",FALSE,-,"Only patent references, impossible to proove it true or false.",new
TTNPB,ABCA1,SJOGREN'S SYNDROME,"Medline_11355874,Patent_WO2017123795A1",TRUE,Human ABCA1 contains a large amino-terminal extracellular domain homologous to an epitope of Sjögren's Syndrome.,"Patent_US20060009520,Patent_US20060009520A1,Medline_14560020",TRUE,Retinoic acid receptor (RAR) activators (all-trans-retinoic acid [ATRA] and TTNPB) were found to increase ATP-binding cassette transporter 1 (ABCA1) mRNA and protein in macrophages. ,,new
DORZOLAMIDE,CA2,SJOGREN'S SYNDROME,"Medline_8613065,Medline_17622741",TRUE,The results suggest that carbonic anhydrase II is one candidate target antigen recognized during the autoimmune pathophysiology observed in idiopathic chronic pancreatitis and Sjögren's syndrome.,"Medline_23317571,Patent_US20150283265,Patent_US20140056815,Patent_US20130309278,Patent_US20100125067,Patent_US20140336514,Medline_8070313,Pmcoa_5238551,Pmcoa_2993108",TRUE,"Compound 29 exhibits weak potency (pEC(50)=5.7, IA>1.0) as an FP agonist with high binding affinity (pK(i)=8.1) to the CA-II enzyme, and has comparable corneal permeability to the CA-II inhibitor dorzolamide.",,new
DIURETIC C,CA2,SJOGREN'S SYNDROME,"Medline_8613065,Medline_17622741",TRUE,,"Patent_EP2758424A1,Patent_WO2013041487A1,Pmcoa_4464172,Patent_US20150299688,Pmcoa_2891608,Medline_20533306,Pmcoa_2705510",FALSE,CAII was functional in these experiments based on the observation that pHi recoveries from CO2-induced acidifications were faster and were inhibited by the membrane-permeant CAII inhibitor ethoxzolamide.,,new
PHENYL ACID,LCN1,SJOGREN'S SYNDROME,"Medline_16249071,Patent_WO2016194014A1",TRUE,Our findings suggest that EBV infection may be linked to the pathogenesis of SS and that tear lipocalin can be considered a novel and yet unidentified autoantigen in SS.,"Medline_24043458,Medline_17945179",FALSE,"8-anilino-1-naphthalenesulfonic acid (ANS) is widely used as a probe for locating binding sites of proteins. To characterize the binding sites of tear lipocalin (TL), we studied ANS binding to apoTL by steady-state and time-resolved fluorescence. ",,keep
COASH,LCN1,SJOGREN'S SYNDROME,"Medline_16249071,Patent_WO2016194014A1",TRUE,,"Patent_EP0904396A2,Patent_EP0904396B1",FALSE,-,"Only patent references, impossible to proove it true or false.",new
BENZALDEHYDE,LCN1,SJOGREN'S SYNDROME,"Medline_16249071,Patent_WO2016194014A1",TRUE,,"Patent_EP1472258A1,Patent_EP1472258B1",FALSE,-,"Only patent references, impossible to proove it true or false.",new
CROMOLYN,MSN,SJOGREN'S SYNDROME,"Medline_29557737,Patent_EP2624851B1,Patent_WO2012045273A1,Patent_US20130210678,Patent_US9632098,Patent_EP2624851A1",TRUE,"Univariate analysis revealed that the proportion of individuals positive for serum IgG against recombinant human moesin was 42 % in a group of Chinese Hans SS patients (21 of 50), 22 % in systemic lupus erythematosus patients and (11 of 50), compared to only 4 % in healthy controls (2 of 50).","Patent_US20110195924,Patent_WO2010042504A1,Patent_US20090062319,Medline_10945828",TRUE,Cromolyn appeared to induce clustering of moesin around secretory granules.,,keep
DOXORUBICIN HYDROCHLORIDE,MSN,SJOGREN'S SYNDROME,"Medline_29557737,Patent_EP2624851B1,Patent_WO2012045273A1,Patent_US20130210678,Patent_US9632098,Patent_EP2624851A1",TRUE,,"Pmcoa_5342538,Medline_28776488,Medline_23598077,Pmcoa_5191581,Pmcoa_4299401,Pmcoa_4550540",FALSE,,,keep
OREGOVOMAB,MUC16,SJOGREN'S SYNDROME,"Medline_19122828,Patent_US20120252756",TRUE,These results demonstrate that SS subjects display a significant increase in both soluble MUC16 and MUC16 mRNA concentrations compared to other forms of aqueous deficient dry eye and non dry-eyed individuals.,"Pmcoa_3253445,Patent_WO2003104429A2,Patent_US20070073047,Patent_WO2003059256A2,Pmcoa_3034919",TRUE,The formation of the oregovomab-CA125 complex results in the development of CA125-specific immune response [150].,,new
TOLCAPONE,TTR,SJOGREN'S SYNDROME,"Medline_20715466,Medline_26339445",TRUE,"As far as our knowledge, this is the 1st report of transthyretin amyloidosis with Sjögren syndrome.","Patent_EP2770988A1,Patent_EP2770988B1,Patent_US20170304243,Patent_US20140296188,Patent_US9610270,Patent_WO2013060668A1,Pmcoa_4766415,Medline_26902880,Pmcoa_5328956,Pmcoa_5428290",TRUE,"Crystal structures of tolcapone bound to wild-type TTR and to the V122I cardiomyopathy-associated variant show that it docks better into the TTR T4 pocket than tafamidis, so far the only drug on the market to treat TTR amyloidoses.",,keep
VARLILUMAB,CD27,SYSTEMIC LUPUS ERYTHEMATOSUS,"Medline_8938100,Medline_7641505,Medline_26713408,Medline_25156507,Pmcoa_2039801",TRUE,"In conclusion, sCD27 serum levels were increased in SLE patients and this increase was associated with the activity of the disease.","Medline_28500025,Pmcoa_4649460",TRUE,"We have developed an agonist anti-human CD27 antibody, varlilumab, and have previously demonstrated its anti-tumor efficacy in several syngeneic tumor models using human CD27 transgenic mice. ",,keep
MILATUZUMAB,CD74,SYSTEMIC LUPUS ERYTHEMATOSUS,"Patent_EP2605788A2,Patent_WO2012024223A2,Medline_28219888,Patent_US20170266281,Patent_US20160279239,Medline_27752708",TRUE,"This investigation establishes the direct participation of CD74 in autoimmunity and highlights a potential role for CD74 in kidney TECs, together with professional APCs in systemic lupus erythematosus.","Patent_EP2552483A1,Patent_US20130164214,Patent_WO2011123428A1,Patent_US20110243841,Patent_US20170088619,Pmcoa_3200112,Patent_US20100272636,Patent_US8367037,Patent_US8846002,Patent_US20120100068,Patent_US20130142729,Patent_US8119101,Medline_20574049,Medline_21417823,Patent_US20170266281,Patent_US20160279239,Pmcoa_4585214,Patent_US20150196662,Patent_US9107960,Patent_US9522959,Patent_US20150196653,Patent_US20170165370,Patent_US9629926,Patent_EP2900277A1,Patent_US20150196661,Patent_WO2016057398A1,Patent_US20150196654,Patent_US20150216997,Patent_US20160032004,Patent_US20170014403,Patent_WO2016210108A1,Patent_EP3024460A2,Patent_EP3204018A1,Patent_US20150202320,Patent_US20150196666,Patent_US20150202319,Patent_US9028833,Patent_US9375489,Patent_US9458242,Patent_WO2017004144A1,Patent_US20160296633,Patent_US20170274093,Patent_US20140227180,Patent_US20160090423,Patent_US20160256562,Patent_US20160303253,Patent_US9493573,Patent_WO2014092804A1,Patent_US20150196665,Patent_US9499631,Patent_US9707302,Patent_US20140219914,Patent_US20160095939,Patent_US9481732,Patent_US20140170063,Patent_US9226973,Patent_WO2015012904A2,Patent_US20150196664,Patent_US9475884,Patent_US20150306243,Patent_US9493574,Patent_US9855344,Pmcoa_3446420,Medline_21228331",TRUE,"Milatuzumab binds to CD74 and promotes internalization of the antibody-CD74 complex, thus delivering conjugated antitumoral agents inside tumor cells with high CD74 expression, but not to normal cells with low CD74 levels (85).",,keep
CLAZAKIZUMAB,CDR1,SYSTEMIC LUPUS ERYTHEMATOSUS,"Medline_18209054,Medline_12937633,Patent_US20090148405",TRUE,"Thus, hCDR1 down-regulates Akt phosphorylation, which leads to up-regulated expression of T cell Egr-2 and Egr-3, resulting in the inhibition of IFN-gamma secretion that is required for the maintenance of SLE.","Patent_WO2012071561A2,Patent_EP2643016A2",FALSE,-,"Only patent references, impossible to proove it true or false.",new
OCTYL GLUCOSIDE,DNASE1,SYSTEMIC LUPUS ERYTHEMATOSUS,"Medline_16606442,Medline_19181929,Medline_19844716,Medline_15569484,Medline_26879320,Medline_23183758,Medline_19863681,Medline_4738335,Medline_5462671,Medline_9158089,Pmcoa_1526614,Pmcoa_5006695,Patent_EP0854927B1,Patent_EP0910647A1,Patent_EP0910647B1,Patent_EP1980618A2,Patent_US20080293121,Patent_US20020173025,Patent_US20050170365,Patent_US6348343,Patent_WO1996026279A1,Patent_US7407785,Patent_US6391607,Medline_15333586,Medline_10835632,Patent_EP1635798A2,Patent_WO2005000282A2",TRUE,"In conclusion, our findings confirm that DNase I is low in SLE and suggest that it may play a role in apoptosis in SLE by regulating the surface expression of the cell death molecule Fas.","Patent_US5976567,Patent_US20070172950,Patent_US5705385",FALSE,-,"Only patent references, impossible to proove it true or false.",new
APRACLONIDINE,LBR,SYSTEMIC LUPUS ERYTHEMATOSUS,"Medline_2766336,Medline_3112222",FALSE,Peripheral lymphocytes stimulated with phytohemagglutinin (PHA-blasts) were examined for their responsiveness to exogenous interleukin 2 (IL-2). The proliferative response of PHA-blasts to IL-2 was significantly lower in patients with systemic lupus erythematosus (SLE) than in normal subjects.,"Patent_US20170027991,Patent_US9415036",-,,,new
CHEMBL2402737,MDM2,SYSTEMIC LUPUS ERYTHEMATOSUS,"Medline_29324237,Pmcoa_4451996,Medline_26090506,Medline_21949095",TRUE,"In conclusion, our data suggested that apoptosis, cfDNA and MDM2 could form a pathological axis in SLE, especially in pSLE.","Pmcoa_5683421,Pmcoa_5946445,Pmcoa_5674101,Pmcoa_5814445,Medline_26586447,Medline_26993060,Medline_27353420,Medline_29392451,Medline_29368050,Pmcoa_5331088,Pmcoa_4924270,Pmcoa_5652019,Pmcoa_5743003,Pmcoa_5833874",TRUE,"For these studies, we used the MDM2 inhibitor, Idasanutlin, which is currently in clinical trials for many malignancies37. ",,keep
CHEMBL3186011,MDM2,SYSTEMIC LUPUS ERYTHEMATOSUS,"Medline_29324237,Pmcoa_4451996,Medline_26090506,Medline_21949095",TRUE,,"Pmcoa_3382884,Pmcoa_4737887",TRUE,"Since several compounds that disrupt p53-Mdm2 binding are now being tested in the clinic, these results may have profound implications for the future clinical use of both APR-246 and inhibitors of p53-Mdm2 binding.",,keep
QUINOLINOL,MDM2,SYSTEMIC LUPUS ERYTHEMATOSUS,"Medline_29324237,Pmcoa_4451996,Medline_26090506,Medline_21949095",TRUE,,"Medline_16789731,Patent_WO2017066245A1",TRUE, This quinolinol binds to MDM2 with a Ki of 120 nM and activates p53 in cancer cells with a mechanism of action consistent with targeting the MDM2-p53 interaction.,,new
CHEMBL3039523,MECP2,SYSTEMIC LUPUS ERYTHEMATOSUS,"Patent_US20090246768,Pmcoa_3817542,Medline_26782401,Medline_18320046,Pmcoa_2253825",TRUE,Eight out of the nine SNPs are within the MECP2 gene and showed significant association with SLE ,"Medline_29755109,Patent_US20170291934",FALSE,The purpose of this study was to determine if localized delivery of IL-12 encoded by a replication-incompetent adenoviral vector engineered to express IL-12 via a RheoSwitch Therapeutic System® (RTS®) gene switch (Ad-RTS-IL-12) administered intratumorally which is inducibly controlled by the oral activator veledimex is an effective approach for glioma therapy.,,new
NSC338720,MX1,SYSTEMIC LUPUS ERYTHEMATOSUS,"Pmcoa_5763828,Medline_22859983,Medline_26175399,Pmcoa_3408474,Medline_19462904",TRUE,"IFNβ induced higher levels of the IFN-I-dependent MxA protein mRNA in SLE than in healthy controls, whereas the opposite was observed for SOCS1. ","Patent_US20060173051,Patent_EP1846373B1,Patent_US7122563,Pmcoa_2717391",FALSE,"Derivatives were prepared from DM-PEN and evaluated in vivo against human U251 glioblastoma, D54 glioblastoma and MX-1 breast tumor xenografts and mammary tumor 16/C that were implanted in the mammary fat pad or intracranially (IC).",,new
"(R)-(METHYL [(5E,8E,11E,14E)-ICOSA-5,8,11,14-TETRAEN-1-YL]PHOSPHONOFLUORIDATE)",PLA2G7,SYSTEMIC LUPUS ERYTHEMATOSUS,"Medline_1424155,Medline_2354868,Pmcoa_2834121",TRUE,"The association between PAF-AH and LDL adds support to the notion that PAF-AH, which binds to LDL, might contribute to atherogenesis in SLE patients.","Pmcoa_3966846,Medline_24671173",TRUE,"MAFP, a specific PAF-AH inhibitor, could significantly reduce PAF-AH activity and therefore worsen lung inflammation in LPS-challenged F508del mice.",,keep
MD 805,SERPINC1,SYSTEMIC LUPUS ERYTHEMATOSUS,"Medline_6826782,Medline_6442639",TRUE,"At-III deficiency does not appear to be an inherent feature of SLE, and reduced activities should only be anticipated when there are specific aetiological factors present, such as massive proteinuria, extensive hepatic disease, or active thrombosis.","Medline_2264021,Medline_1920862",TRUE,MD805 also inhibited the formation of thrombin-ATIII complex.,,new
ALTRETAMINE,TGM2,SYSTEMIC LUPUS ERYTHEMATOSUS,"Medline_12455168,Medline_15176659",TRUE, The aim of this study was to determine the prevalence of antitissue transglutaminase (anti-tTG) in SLE and the relation between SLE and CD. ,"Patent_US9206423,Patent_US20160215285,Patent_US20140187607",FALSE,-,"Only patent references, impossible to proove it true or false.",new
ROMIPLOSTIM,TPO,SYSTEMIC LUPUS ERYTHEMATOSUS,"Medline_28544477,Medline_28712818,Patent_WO2012031122A2",TRUE," We calculated the rate of these thyroid diseases and positive antibodies to thyroglobulin (ATGAb), thyroid peroxidase (TPOAb) in SLE patients grouped by the presence of overlap syndrome and anti-dsDNA antibody.","Patent_WO2014100636A2,Pmcoa_4377333,Pmcoa_2900600,Pmcoa_3269797,Medline_19642221,Pmcoa_2802075",FALSE,Romiplostim is an Fc-peptide fusion protein that activates intracellular transcriptional pathways via the thrombopoietin (TPO) receptor leading to increased platelet production. ,,keep
